



Meningeal $\gamma\delta$ T cells regulate anxiety-like behavior via IL-17a signaling in neurons

Kalil Alves de Lima^{1,2,3}✉, Justin Rustenhoven^{1,2,3,7}, Sandro Da Mesquita^{1,2,7}, Morgan Wall^{1,2,7}, Andrea Francesca Salvador^{1,2,3}, Igor Smirnov^{1,2,3}, Guilherme Martellosi Cebinelli^{1,2,4}, Tornike Mamuladze^{1,2,3}, Wendy Baker^{1,2}, Zach Papadopoulos^{1,2,3}, Maria Beatriz Lopes⁵, William Sam Cao⁶, Xinmin Simon Xie⁶, Jasmin Herz^{1,2,3} and Jonathan Kipnis^{1,2,3}✉

Interleukin (IL)-17a has been highly conserved during evolution of the vertebrate immune system and widely studied in contexts of infection and autoimmunity. Studies suggest that IL-17a promotes behavioral changes in experimental models of autism and aggregation behavior in worms. Here, through a cellular and molecular characterization of meningeal $\gamma\delta$ 17 T cells, we defined the nearest central nervous system-associated source of IL-17a under homeostasis. Meningeal $\gamma\delta$ T cells express high levels of the chemokine receptor CXCR6 and seed meninges shortly after birth. Physiological release of IL-17a by these cells was correlated with anxiety-like behavior in mice and was partially dependent on T cell receptor engagement and commensal-derived signals. IL-17a receptor was expressed in cortical glutamatergic neurons under steady state and its genetic deletion decreased anxiety-like behavior in mice. Our findings suggest that IL-17a production by meningeal $\gamma\delta$ 17 T cells represents an evolutionary bridge between this conserved anti-pathogen molecule and survival behavioral traits in vertebrates.

Infectious pathogens are among the strongest selective forces in mammalian evolution, allowing resistance alleles to emerge and spread over time. The host inflammatory response to such pathogens is orchestrated predominantly by cytokines, which may have evolved to shunt energy resources into fighting infectious agents and altering host behavior to avoid death from pathogen exposure¹. Recently, a rich diversity of immune cells in the healthy mouse meninges have been described, where they are ideally positioned for immune surveillance of the central nervous system (CNS) and its borders². Meningeal immune cells, and their derived cytokines, have also been shown to affect brain functions, including sociability and spatial learning^{3,4}. Here, we sought to identify and explore additional meningeal immune populations with the potential to impact brain functions. We uncovered the molecular mechanisms by which physiological levels of interleukin-17a (IL-17a) derived from dural-associated $\gamma\delta$ 17 T cells control anxiety-like behavior in mice through neuronal IL-17Ra signaling. Our findings provide new insights into the neuroimmune interactions at the meningeal-brain interface and support further research into new therapies for neuropsychiatric conditions.

Results

Steady-state meninges harbor a CNS-associated source of IL-17a.

Using mass cytometry (CyTOF) to conduct a broad immunophenotyping analysis of the dural meningeal immune compartment, we identified a cluster of CD3⁺ T cells lacking expression of the conventional T cell coreceptors CD4 and CD8 (Fig. 1a). Flow cytometric analysis revealed a high representation of $\gamma\delta$ T cell receptor (TCR)-expressing cells in the double negative T cell fraction (Extended Data Fig. 1a)—a recently reported population in the

meninges^{5,6}. High-dimensional analysis by CyTOF revealed a high proportion of $\gamma\delta$ TCR-positive cells expressing chemokine receptor 6 (CCR6), activation markers CD44 and CD69 and the lineage-defining transcription factor of IL-17a-producing $\gamma\delta$ T cells ($\gamma\delta$ 17 T cells), ROR γ t (retinoic acid-related orphan receptor gamma t; Fig. 1b). Similar results were obtained by flow cytometry staining (Extended Data Fig. 1b). Mirroring their ROR γ t expression, the dural meninges demonstrated enrichment in $\gamma\delta$ T cells expressing IL-17a upon ex vivo stimulation, which comprised more than 95% of the potential cytokine source in the meningeal space (Fig. 1c and Extended Data Fig. 1c,d).

To assess $\gamma\delta$ T cell distribution in additional CNS-associated barriers, we micro-dissected border regions and performed flow cytometry analysis. $\gamma\delta$ T cells were highly prevalent in the dura mater compared with samples obtained from subdural meninges (leptomeninges, comprising pia and arachnoid), the choroid plexus or the brain parenchyma (Extended Data Fig. 1e). Similar $\gamma\delta$ T cell populations were also detected in fresh autopsy samples of human dura, with fewer cells present in the arachnoid mater (Extended Data Fig. 1f).

To visualize the spatial localization of these intradural $\gamma\delta$ 17 T cells, we relied on whole-mount immunostaining of healthy mouse meninges. Since $\gamma\delta$ TCR staining has proven to be challenging by commercial antibodies, we generated a tamoxifen-inducible *Tcrd*^{CreERT2}:Ai6 $\gamma\delta$ T cell reporter line, and through co-staining with anti-CD3 observed a high concentration of these cells restricted to regions along the dural sinuses (Fig. 1d). Collectively, these findings indicate that $\gamma\delta$ 17 T cells are situated in the dural meninges and constitute the nearest CNS-related potential source of IL-17a under steady-state conditions.

¹Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA. ²Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, VA, USA. ³Department of Pathology and Immunology, Division of Immunobiology, Washington University, St. Louis, MO, USA. ⁴Center for Research on Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil. ⁵Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, USA. ⁶AfaSci Research Laboratories, Redwood City, CA, USA. ⁷These authors contributed equally: Justin Rustenhoven, Sandro Da Mesquita, Morgan Wall. ✉e-mail: alvesdelima@wustl.edu; kipnis@wustl.edu




Fig. 1 | Dural meninges harbor $\gamma\delta 17$ T cells. **a**, Mass cytometry analysis of immune cells isolated from steady-state meninges of naive animals. Meningeal T cells ($CD3^+Thy1.2^+$) were clustered as $CD4^+$, $CD8^+$ or double negative (DN). t-SNE, t-distributed stochastic neighbor embedding. **b**, Expression of T cell markers in meningeal $\gamma\delta$ T cells, $CD4^+$ and $CD8^+$ $\alpha\beta$ T cells analyzed by mass cytometry ($n=8$ pooled mice; each dot represents one cell). Statistical significance was determined by Wilcoxon rank-sum test with Benjamini–Hochberg post-hoc adjustments. Data represent one single experiment. NS, not significant. **c**, Left: expression of IL-17a, IFN- γ and IL-22 in meningeal $\gamma\delta$ T cells, conventional $\alpha\beta$ T cells (TCR $\beta^+NK1.1^{neg}$) and natural killer (NK) T lymphocytes (TCR $\beta^+NK1.1^+$) by flow cytometric analysis. Right: contribution of each isolated population to total IL-17a, IFN- γ and IL-22 expression in steady-state meninges using backgating analysis. **d**, Meningeal whole mounts stained for CD3 (red) and CD31 (blue), showing the presence of $\gamma\delta$ T cells ($CD3^+TCR\delta$ (ZsGreen) $^+$ cells; in yellow). SSS, superior sagittal sinus; TS, transverse sinus. Scale bars, 200 μ m (left) and 100 μ m (right). Images are representative of three independent experiments with similar results ($n=3$ in each experiment). **e**, Absolute numbers of meningeal $\gamma\delta$ T cells isolated from postnatal animals at P1, P3 and P7 and adults (8 weeks old) analyzed by flow cytometry ($n=10$ (P1); $n=7$ (P3); $n=5$ (P7); $n=5$ (adult)). Statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparisons test. **f**, Left: Ki67 expression in the meningeal $\gamma\delta$ T cells depicted in **e**. Right: percentage of proliferating Ki67 hi $\gamma\delta$ T cells isolated from postnatal mice. Statistical significance was determined by one-way ANOVA followed by Bonferroni's multiple comparisons test. Data were pooled from two independent experiments with similar results. Data are shown as means \pm s.e.m. and each data point represents an individual mouse.

$\gamma\delta 17$ T cells populate meninges shortly after birth and are maintained by slow self-renewal. $\gamma\delta$ T cells are the first T cells generated during embryonic development and rapidly seed peripheral tissues where specialized subsets are maintained for life as tissue-resident cells. To determine the migratory kinetics of meningeal $\gamma\delta 17$ T cells to the dura mater, we obtained tissues from prenatal, neonatal and adult mice. Flow cytometry analysis revealed that $\gamma\delta$ T cells were virtually absent in prenatal dural meninges (Extended Data Fig. 1g) but displayed a progressive seeding from postnatal day three, with substantial numbers present by day seven (Fig. 1e).

In both humans and mice, $\gamma\delta$ T cells represent a minor part of the circulating T cell compartment; however, certain subsets are present in much higher proportions in barrier tissues such as the skin, gut and reproductive tract⁷. To determine whether meningeal (dural) $\gamma\delta 17$ T cells are constantly replenished from the periphery or represent a long-lived population, we performed parabiotic experiments using congenic CD45.1 and CD45.2 mice. Unlike blood-circulating $\gamma\delta$ T cells, which reached near-complete chimerism after 4 weeks, meningeal $\gamma\delta 17$ T cells were found to originate almost exclusively from the host mice, indicating a tissue-resident phenotype (Extended Data Fig. 1h).

Given the early postnatal seeding and the low chimerism between blood and meninges in adulthood, we hypothesized that highly active $\gamma\delta$ T cells in neonatal meninges undergo rapid local expansion to fill the niche and reach homeostatic numbers in adult mice. In support of this idea, Ki67 staining revealed that meningeal $\gamma\delta 17$ T cells exhibited high homeostatic proliferation at early postnatal periods (P1–7) yet maintained very low proliferation rates in adult mice (Fig. 1f). Corroborating the Ki67 staining, meningeal $\gamma\delta 17$ T cells isolated from neonates displayed higher levels of *in vivo* 5-ethynyl-2'-deoxyuridine (EdU) incorporation compared with adult mice (Extended Data Fig. 1i–k). Taken together, these data indicate that $\gamma\delta$ T cells populate the meninges at perinatal stages and may be maintained by low-rate self-renewal.

Molecular diversity and transcriptional landscape of meningeal $\gamma\delta 17$ T cells. To gain further insight into the molecular diversity and transcriptional landscape of the meningeal $\gamma\delta 17$ T cells, sorted $\gamma\delta$ T cells from the dural meninges and spleen of 7-d-old (P7) or 8-week-old adult mice were profiled using single-cell RNA sequencing (scRNA-Seq). Uniform manifold approximation and projection (UMAP) for dimensionality reduction revealed ten clusters, demonstrating heterogeneity within the $\gamma\delta$ T cell lineage (Fig. 2a).




Fig. 2 | Functional and molecular characterization of meningeal $\gamma\delta 17$ T cells. **a**, UMAP visualization of 1,041 $\gamma\delta$ T cells isolated from adults and neonates (P7), colored by each cluster. **b**, Log-normalized expression per cell of hallmark $\gamma\delta$ T cell markers, with cells ordered by sample. **c**, Mean-centered, log-normalized expression per cell of the top 50 significantly DEGs ($P_{\text{adj}} < 0.05$) between adult meningeal and splenic $\gamma\delta$ T cells ranked by absolute log[fold change]. **d**, Top ten enriched biological processes for the set of significantly DEGs ($P_{\text{adj}} < 0.05$) between adult and P7 meningeal $\gamma\delta$ T cells using two-sided Fisher's exact test with Benjamini–Hochberg corrections (false discovery rate < 0.05). **e**, Expression of chemokine receptors in meningeal and splenic $\gamma\delta$ T cells isolated from adult or P7 mice. **f**, Left: CXCR6-GFP expression on $\gamma\delta$ T cells from adult mice by flow cytometry. Middle: percentage of CXCR6^{hi} meningeal or splenic $\gamma\delta$ T cells. Right: analysis of CXCR6-GFP mean fluorescence intensity (MFI) in $\gamma\delta$ T cells ($n = 6$ (meningeal); $n = 6$ (splenic)). Data are representative of five independent experiments. **g**, Left: frequency of TCR $\gamma\delta$ - or $\alpha\beta$ -expressing cells isolated from CXCR6-sufficient or deficient mice, gated on CD45⁺ live cells. Middle: graph showing the frequency of $\gamma\delta$ T cells ($n = 7$ ($Cxcr6^{+/+}$); $n = 8$ ($Cxcr6^{-/-}$)). Data are pooled from two independent experiments with similar results. Right: absolute numbers of $\gamma\delta$ T cells ($n = 5$ ($Cxcr6^{+/+}$); $n = 6$ ($Cxcr6^{-/-}$)). Data are pooled from two independent experiments with similar results. In **f** and **g**, data are shown as means \pm s.e.m. and each data point represents one mouse. Significance was determined by unpaired two-tailed t -test.

Nonetheless, this cluster distribution was clearly partitioned into two main subsets based on meningeal or splenic origin (Fig. 2a), thereby supporting maximum similarity between meningeal $\gamma\delta$ T cells regardless of the age of the mice.

We then investigated the expression of known hallmark regulators of $\gamma\delta$ T cell subsets. In splenic populations, the genes *Cd27*, *Id3* and *Tbx21* (all characteristic of interferon- γ (IFN- γ)-producing $\gamma\delta$ T cells) were over-represented (Fig. 2b). In contrast with splenic $\gamma\delta$ T cells and in agreement with previous findings, we observed higher representations of transcripts for *Rorc*, *Rora*, *Cd44*, *Sox13*, *Il1r1* and *Il23r* in the meningeal $\gamma\delta 17$ T cells (Fig. 2b). Meningeal $\gamma\delta 17$ T cells were also enriched for *Tcr γ v6* transcripts encoding the TCR-V $\gamma 4$ chain (Garman nomenclature; Extended Data Fig. 2a), which characterizes a subset of fetal thymus-derived $\gamma\delta 17$ T cells⁷. Further assessment of the TCR-V γ chain representation in the meningeal compartment using three commercially available flow antibodies (V $\gamma 1$, V $\gamma 2$ and V $\gamma 3$) supported these findings (Extended Data Fig. 2b,c).

To identify unique meningeal $\gamma\delta 17$ T cell-related transcripts, we assessed differentially expressed genes (DEGs) between the meningeal and splenic subsets. While meningeal $\gamma\delta 17$ T cells shared many functional genes (such as *Maf*, *Blk* and *Cd163l1*) with their IL-17a-producing counterparts residing in other tissues, the functional roles of a sizeable number of genes remain unexplored (Fig. 2c). Notably, we noticed substantial expression of *Slc6a13* transcripts in meningeal $\gamma\delta 17$ T cells (Fig. 2b and Extended Data Fig. 2d)—a solute carrier responsible for the gamma-aminobutyric acid (GABA) and taurine transporter (GAT2)⁸, a function of which may relate to their location and should be further explored.

Next, we performed gene set enrichment analysis for Gene Ontology biological processes in the set of transcripts differentially expressed between meningeal $\gamma\delta 17$ T cells isolated from P7 and adult mice. Our results demonstrated enrichment of biological processes that participate in cell cycle and DNA replication in P7 meningeal $\gamma\delta 17$ T cells (Fig. 2d). In summary, these findings reveal




Fig. 3 | Meningeal $\gamma\delta 17$ T cells regulate anxiety-like behavior. **a**, Left: cumulative movement of wild-type (WT) and $\gamma\delta$ T cell-deficient ($Tcrd^{-/-}$) mice in the elevated plus maze. Right: percentage of time spent in the open arms of the maze ($n = 18$ (WT); $n = 20$ ($Tcrd^{-/-}$)). The results of two independent experiments were pooled. **b**, Left: cumulated movement of WT and $Tcrd^{-/-}$ animals in the open field test. Middle: total ambulatory distance in the arena. Right: percentage of time spent in the center of the arena ($n = 8$ (WT); $n = 8$ ($Tcrd^{-/-}$)). **c**, WT mice were injected (intra-cisterna magna) with $2.5 \mu\text{g}$ anti-TCR $\gamma\delta$ or isotype control and 3 d later assessed in the elevated plus maze. Left: cumulated movement of isotype control- or anti-TCR $\gamma\delta$ -injected mice. Right: percentage of time spent in the open arms of the maze ($n = 15$ (isotype control); $n = 16$ (anti-TCR $\gamma\delta$)). The results were pooled from two independent experiments. **d**, WT mice were injected with anti-TCR $\gamma\delta$ or isotype control and 3 d later assessed in the open field task. Left: cumulative movement in the open field arena. Middle: total distance traveled. Right: percentage of time spent in the center of the arena ($n = 16$ (isotype control); $n = 17$ (anti-TCR $\gamma\delta$)). Data were pooled from two independent experiments. In **a–d**, data are expressed as means \pm s.e.m. and each data point represents an individual mouse. Statistical significance was determined by unpaired two-tailed *t*-test.

a transcriptional signature for meningeal $\gamma\delta 17$ T cells and corroborate their higher activation status during early postnatal stages.

CXCR6 is highly expressed in meningeal $\gamma\delta 17$ T cells. Immune cell migration is mediated predominantly by the expression of chemokines and their receptors. Analysis of chemokine receptor expression in each $\gamma\delta$ T cell population revealed a substantial enrichment of CXCR6 (a chemokine receptor highly expressed in activated/memory T cells⁹) on meningeal $\gamma\delta 17$ T cells compared with the spleen (Fig. 2e). Using publicly available scRNA-Seq data⁶, we found that *Cxcl16* (the ligand for CXCR6) was highly expressed in dural-resident myeloid cells (Extended Data Fig. 2e), indicating a potential receptor–ligand axis for its dural recruitment, retention and/or activation. In line with these scRNA-Seq results, we observed high CXCR6 expression on meningeal T cells (Extended Data Fig. 2f), with more than 60% of $\gamma\delta 17$ T cells positive using flow cytometric analysis (Fig. 2f). To examine the functional role of the CXCR6–CXCL16 axis for meningeal $\gamma\delta 17$ T cell trafficking, we isolated the dural meninges from CXCR6-deficient or -sufficient mice. Significantly fewer meningeal $\gamma\delta 17$ T cells were present in mice lacking CXCR6 in both frequency and absolute number (Fig. 2g). Interestingly, the number of conventional $\alpha\beta$ T cells was also decreased by CXCR6 deficiency (Extended Data Fig. 2g). In addition to CXCR6, $\sim 20\%$ of meningeal $\gamma\delta 17$ T cells also expressed CCR2 (Fig. 2e and Extended Data Fig. 2h); however, *Ccr2*^{-/-} mice displayed elevated T cell frequencies and numbers in the meningeal compartment (Extended Data Fig. 2i,j). Collectively, these findings suggest that the CXCR6–CXCL16 axis plays a role in $\gamma\delta 17$ T cell recruitment, retention and/or activation in the dural meninges. Further studies will address its cell-autonomous role, particularly during perinatal stages.

Meningeal $\gamma\delta 17$ T cells control anxiety-like behaviors. Given that aspects of meningeal immunity reportedly affect CNS function in both health and disease^{2,10,11}, we investigated whether mice deficient in $\gamma\delta$ T cells ($Tcrd^{-/-}$) would exhibit any behavioral alterations. Profiling of $Tcrd^{-/-}$ mice in a battery of behavioral tests revealed no deficit in spatial memory task performance, social preference or foraging behavior (Extended Data Fig. 2k–n). However, $\gamma\delta$ T cell-deficient mice exhibited significantly increased exploration times in the open arms of the elevated plus maze test compared with their wild-type littermates (Fig. 3a). Typically, mice tested in the elevated plus maze naturally avoid unprotected open areas, favoring the darker and safer enclosed arms. This conflict between approach–avoidance behaviors capitalizes on the innate, conflicting drives of rodents to explore novelty and to avoid environmental threats—behaviors that are typically thought to reflect the anxiety state of the organism¹².

As another approach to measure anxiety-like behavior, we assessed $\gamma\delta$ T cell-deficient mice in the open field test, in which the typical tendency is to spend more time exploring the periphery and avoid the center of the arena¹³. In agreement with the elevated plus maze findings, the $Tcrd^{-/-}$ mice spent more time in the center of the arena than their wild-type counterparts (Fig. 3b), supporting the notion that mice lacking $\gamma\delta$ T cells show decreased basal levels of vigilance, which we interpreted as decreased anxiety behavior.

Given that $Tcrd^{-/-}$ mice lack $\gamma\delta$ T cells in all tissues from birth, this model cannot be used to determine the specific contribution of the meningeal subset to the observed phenotype. Furthermore, it could be argued that the lack of $\gamma\delta$ T cells during ontogenesis may have pleiotropic effects, complicating our interpretation of the behavior phenotype. To rule out these possibilities and to target meningeal $\gamma\delta 17$ T cells more specifically, we injected anti-TCR $\gamma\delta$

antibodies into the cerebrospinal fluid (CSF; intra-cisterna magna) of wild-type mice, and 3 d later evaluated their performance in the elevated plus maze and open field tests. Of note, this is currently the best available approach to primarily target meningeal immune cells and it has been previously demonstrated that antibodies and tracers injected into the CSF reach meningeal spaces¹⁴. While the complete pathway remains unknown, CSF macromolecules are probably reaching the dura by traversing the arachnoid layer underlying the dural sinuses¹⁵. Supporting the meningeal contribution to the observed phenotype, anti-TCR $\gamma\delta$ treatment decreased anxiety levels of animals in both behavioral assays (Fig. 3c,d). Altogether, these findings suggested that meningeal $\gamma\delta$ 17 T cells might act as homeostatic regulators of anxiety-like behaviors.

Homeostatic activation of meningeal $\gamma\delta$ 17 T cells regulates anxiety-like behavior. Having shown that the use of anti-TCR $\gamma\delta$ antibodies decreased anxiety-like behaviors in mice, we next sought to determine how meningeal $\gamma\delta$ 17 T cells regulate this process. In vivo administration of anti-TCR $\gamma\delta$ monoclonal antibodies was associated with internalization of TCR $\gamma\delta$, without actual loss of the meningeal $\gamma\delta$ T cells (Fig. 4a and Extended Data Fig. 3a,b), similar to what has been previously shown in the intestines¹⁶. It is important to note that in addition to its primarily meningeal specificity, an off-target effect of anti-TCR $\gamma\delta$ treatment was also observed in splenic $\gamma\delta$ T cells (Extended Data Fig. 3c).

We further hypothesized that meningeal $\gamma\delta$ 17 T cells with lower TCR levels on their cell surfaces would become poor responders to TCR-specific stimulation and hence would downregulate the production of IL-17a. To this end, we repeated the intra-cisterna magna injections of anti-TCR $\gamma\delta$ and evaluated the meningeal T cell subsets by flow cytometry. Administration of anti-TCR $\gamma\delta$ decreased the percentage of meningeal IL-17a-producing $\gamma\delta$ T cells as well as the cell-based production of IL-17a (Fig. 4b and Extended Data Fig. 3d). Importantly, TCR $\gamma\delta$ expression, IL-17a production and anxiety levels returned to normal 1 week later, indicating $\gamma\delta$ TCR recycling, antigen engagement and reciprocal regulation of anxiety-like behaviors (Extended Data Fig. 3e,f). Collectively, these observations demonstrate that meningeal $\gamma\delta$ 17 T cells are crucial modulators of anxiety-like behaviors.

The aforementioned findings relied on ex vivo restimulation as a readout for cytokine production. However, this approach detects the potential, but not the true extent, of cytokine production in vivo. We utilized IL-17a-enhanced green fluorescent protein (eGFP) reporter mice to directly assess IL-17a transcription in vivo. Consistent with its steady-state expression, we observed a CD3⁺IL-17a-eGFP⁺ population by immunofluorescence, mainly confined to regions of the dural sinuses (Extended Data Fig. 3g), which mirrored the $\gamma\delta$ T cell distribution (Fig. 1d). Flow cytometry analysis revealed restricted expression of IL-17a-eGFP in freshly isolated meningeal $\gamma\delta$ 17 T cells with virtual absence in their splenic counterparts (Fig. 4c and Extended Data Fig. 3h). Notably, this baseline expression was downregulated following anti-TCR $\gamma\delta$ treatment (Extended Data Fig. 3i). Taken together, these findings demonstrate that meningeal $\gamma\delta$ 17 T cells are actively expressing IL-17a under steady state and that TCR engagement partially regulates this process.

Meningeal $\gamma\delta$ 17 cells were distributed along the dural sinuses, which drain blood from the brain into the internal jugular veins¹⁷. To determine whether the $\gamma\delta$ 17 T cells are tissue localized and thus constantly release IL-17a within the meningeal stroma, we injected intravenously fluorescently labeled anti-CD45 antibodies and assessed $\gamma\delta$ T cells for labeling. More than 99% of blood-circulating $\gamma\delta$ T cells were stained with the intravenous anti-CD45, while only 1–2% of meningeal $\gamma\delta$ 17 T cells were labeled (Extended Data Fig. 3j), suggesting their localization to dural parenchyma. Immunostaining of coronal sections of the dura mater obtained from IL-17a-eGFP mice confirmed this parenchymal localization (Extended Data

Fig. 3k). IL-17a detection in dural meningeal homogenates from wild-type but not *Tcrd*^{-/-} mice further suggests that IL-17a is probably released by $\gamma\delta$ 17 T cells in the meningeal stroma (Fig. 4d). It is noteworthy that CSF levels of IL-17a were below the technical limits of detection (Extended Data Fig. 3l); however, its plasma levels were comparable between groups (Extended Data Fig. 4m). Collectively, these results demonstrate that meningeal $\gamma\delta$ 17 T cells are bona fide tissue-localized cells and the nearest CNS-associated source of IL-17a under homeostasis.

Molecular mediators regulating IL-17a production by meningeal $\gamma\delta$ 17 T cells. $\gamma\delta$ T cells express many receptors that regulate their responsiveness to the environment⁷. As such, we next investigated the ability of several endogenous and exogenous stimuli to modulate IL-17a production in meningeal $\gamma\delta$ 17 T cells. Physical and mental stress have been frequently correlated with an increased risk of developing anxiety disorders¹³. However, neither seven consecutive days of electrical foot shock nor unpredictable chronic mild stress over 8 weeks modulated IL-17a expression in meningeal $\gamma\delta$ T cells (Extended Data Fig. 4a,b).

While the identities of TCR ligands for $\gamma\delta$ T cells have been obscure, some reports suggest that commensal bacteria are necessary for their expansion and activation, via direct or indirect pathways¹⁸. Abnormal behaviors have also been reported in the absence of microbiota, including decreased anxiety-like behavior in the elevated plus maze¹⁹. Next, we tested whether commensals may, in part, modulate IL-17a production by meningeal $\gamma\delta$ 17 T cells. Although the disruption of the commensal microbiota with broad-spectrum antibiotics and the use of germ-free mice did not affect meningeal $\gamma\delta$ 17 T cell numbers, we found a mild, but significant, decrease of IL-17a transcription by these cells (Fig. 4e,f and Extended Data Fig. 4c,d). Moreover, acute peripheral lipopolysaccharide (LPS) injection, a pathogen-associated molecular pattern and stimulation of the aryl hydrocarbon receptor increased IL-17a expression in meningeal $\gamma\delta$ 17 T cells (Fig. 4g and Extended Data Fig. 4e, respectively). Deficiency of IL-1R or IL-23, known to promote IL-17a production in T cells, did not alter the number of $\gamma\delta$ 17 T cells or their IL-17a production following ex vivo stimulation (Extended Data Fig. 4f–i). Likewise, a chronic neuroinflammation characteristic of experimental autoimmune encephalomyelitis (EAE) had no effect on IL-17a expression by $\gamma\delta$ 17 T cells (Extended Data Fig. 4j,k). Taken together, these findings suggest that meningeal $\gamma\delta$ 17 T cells are pre-programmed to quickly respond independent of microbiota and inflammatory signals (IL-1 β and IL-23), but pathogen/commensal-derived signals affect their basal transcription of IL-17a.

IL-17a signaling through cortical neurons regulates anxiety-like behavior. On the basis of our aforementioned finding of TCR-dependent downregulation of IL-17a by anti-TCR $\gamma\delta$ treatment in mice, we next sought to determine whether IL-17a deficiency would recapitulate the behavioral abnormalities observed after the functional depletion of meningeal $\gamma\delta$ 17 T cells. We first tested behavior in global IL-17a-deficient mice. In agreement with our previous observations, *Il17a*^{-/-} mice spent significantly more time in the open arms than their heterozygous littermate controls (Extended Data Fig. 5a). Consistent with a meningeal-CSF route, injection of neutralizing antibodies for IL-17a into the CSF of wild-type mice decreased anxiety-like behavior (Fig. 5a). A single injection of recombinant IL-17a into the CSF of *Tcrd*^{-/-} mice was sufficient to increase anxiety levels when tested in the elevated plus maze 3 h after injection (Fig. 5b). Collectively, these findings further support the reciprocal link between meningeal $\gamma\delta$ 17 T cells, IL-17a production by these cells and homeostatic brain function.

To assess a situation as threatening and render an anxiety-like response, an individual must first detect environmental stimuli




Fig. 5 | IL-17a signaling through cortical neurons regulates anxiety-like behavior. **a**, Left: cumulated movement of isotype control- or anti-IL-17a-injected mice in the elevated plus maze 14 h after treatment. Right: percentage of time spent in the open arms of the plus maze ($n=18$ (isotype control); $n=18$ (anti-IL-17a)). Data were pooled from two independent experiments. **b**, $Tcrd^{-/-}$ animals were given 25 ng recombinant IL-17a or aCSF intra-cisterna magna and after 3 h were tested in the elevated plus maze. Left: total movement in the maze. Right: percentage of total time spent in the open arms ($n=14$ (aCSF); $n=12$ (IL-17a)). Data were pooled from two independent experiments with similar results. **c**, Expression of *I17ra* (cyan) within the PFC regions of naive mice according to cortical layers. ACAd, dorsal anterior cingulate cortex; ILA, infralimbic cortex; ORBm, medial orbitofrontal cortex; PrL, prelimbic cortex. Scale bar, 500 μm . The image is representative of five independent experiments ($n=3$ in each experiment). **d**, *I17ra* (cyan) expression on GABAergic (*Gad2*; green) and glutamatergic neurons (*Slc17a7*; magenta) in the mouse mPFC (top) and hippocampus (bottom). DAPI staining is shown in blue. Scale bars, 100 μm . Images are representative of three independent experiments with similar results ($n=3$ in each experiment). **e**, Top: experimental approach used to ablate the IL-17a signaling in mPFC neurons. AAV *SynT^{Cre}* was bilaterally injected into the mPFC of wild-type or *I17ra^{fl/fl}* mice. Mice were tested in the elevated plus maze 4 weeks later. Bottom left: total movement in the maze. Bottom right: percentage of total time spent in the open arms of the maze ($n=10$ (WT: AAV *SynT^{Cre}*); $n=9$ (*I17ra^{fl/fl}*: AAV *SynT^{Cre}*)). Data are expressed as means \pm s.e.m. and each data point represents an individual mouse. Statistical significance was determined by unpaired two-tailed *t*-test.

Fig. 6d), supporting the preferential IL-17Ra expression in cortical glutamatergic neurons.

To better understand the transcriptomic changes associated with a lack of IL-17a signaling in mPFC neurons, we further investigated the DEGs between groups. Overall, we did not find any striking difference in the representation of individual clusters (Extended Data Fig. 6e), but we observed over 300 DEGs, in which the great majority were enriched in neurons annotated for the cortical layers II/III (Fig. 6d and Extended Data Fig. 6f,g). Notably, a significant proportion of these genes are also dysregulated in anxiety and depression disorders, including *Htr2c*, *Htr4*, *Htr7* and *Grm5* (Fig. 6e and Extended Data Fig. 6h). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis performed with upregulated genes in the absence of neuronal IL-17a signaling revealed several enriched processes involved in GABA–benzodiazepine activity (Fig. 6f and Extended Data Fig. 6i), the prototypical target system for anxiolytic drugs¹³. Altogether, these observations demonstrate that homeostatic neuronal IL-17a signaling shapes the transcriptional landscape of mPFC neurons and might be correlated with the behavioral changes in the anxiety state of the organism.

To explore whether these transcriptional changes occur in parallel with changes in synaptic transmission, we used whole-cell patch clamp recordings from layer II/III mPFC neurons to measure the spontaneous excitatory or inhibitory postsynaptic currents (sEPSCs and sIPSCs, respectively; Extended Data Fig. 7). Consistent

with changes in the properties of neurotransmitter release, we observed a significant increase in the frequency, but not amplitude, of sEPSCs in neurons exposed to 10 ng ml⁻¹ IL-17a (Extended Data Figs. 7c and 7d, respectively). No significant changes were found in any parameter evaluated for the sIPSCs (Extended Data Fig. 7g–i). We also saw no changes in the evoked action potentials (Extended Data Fig. 8a,b), suggesting that IL-17a signaling does not contribute to the intrinsic neuronal excitability. Additionally, IL-17a injection directly into the mouse CSF increased neuronal activation in the mPFC, as seen by the quantification of *c-Fos*⁺ cells—a marker of early neuronal activation (Extended Data Fig. 8c). These results suggest that basal neuronal IL-17a signaling contributes to proper neurotransmitter release from excitatory presynaptic terminals of mPFC neurons, thus regulating anxiety-like traits in mice.

Discussion

Here, we provide molecular and functional insights into how a population of $\gamma\delta$ 17 T cells seeds the meningeal spaces and controls anxiety-like behavior in mice through neuronal IL-17Ra signaling.

Previously described non-immune properties of IL-17 included: (1) the regulation of social behavior in maternal immune activation models^{20,21}; (2) body temperature^{22,23}; and (3) neuromodulation in *Caenorhabditis elegans*²⁴. More recently, meningeal $\gamma\delta$ T cells were linked to short-term memory via IL-17a signaling in glial cells⁵. In our hands, using another hippocampal-dependent task,




Fig. 6 | Neuronal IL-17a signaling shapes the transcriptional landscape of mPFC neurons. **a**, Schematic of the experimental approach used to perform sNuc-Seq from mPFC neurons in the absence of neuronal IL-17a signaling. **b**, Left: UMAP projection of nuclei isolated from the mPFC, colored by cluster membership. Right: UMAP projection indicating subpopulations of neurons based on the expression of cortical layer and excitatory and inhibitory genetic markers. NDNF, neuron-derived neurotrophic factor; PV, parvalbumin; SOM, somatostatin; VIP, vasoactive intestinal peptide. **c**, UMAP projection colored by the expression of *Il17ra*. **d**, Overlap among cortical layers in significantly DEGs found between both *Syn^{T^{Cre}}*/*Il17ra^{fl/fl}* versus *Syn^{T^{Cre}}* and *Syn^{T^{Cre}}*/*Il17ra^{fl/fl}* versus *Il17ra^{fl/fl}*, based on the layers identified in **b**. **e**, Heatmap of DEGs between both *Syn^{T^{Cre}}*/*Il17ra^{fl/fl}* versus *Syn^{T^{Cre}}* and *Syn^{T^{Cre}}*/*Il17ra^{fl/fl}* versus *Il17ra^{fl/fl}* in layer II/III. **f**, Significantly enriched Gene Ontology terms for the set of significantly upregulated (left) and downregulated genes (right) in *Syn^{T^{Cre}}*/*Il17ra^{fl/fl}* as compared with both *Syn^{T^{Cre}}* and *Il17ra^{fl/fl}* in layer II/III. Colors indicate the Benjamini–Hochberg P_{adj} value and dot sizes indicate the number of genes contributing to the enrichment of the term. AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.

$\gamma\delta$ T cell knockout mice did not exhibit learning deficits, and IL-17Ra expression was highly concentrated to cortical neurons, with low to no expression in the hippocampus.

Injection of antibodies (anti-IL-17a and anti-TCR $\gamma\delta$) into the cisterna magna led to decreased anxiety-like behavior and suggested that the physiological release of IL-17a in the meningeal–brain interface contributes to the anxiety state of the organism. However, a peripheral leak of these antibodies does not rule out the contribution of blood-derived IL-17a in our behavioral readouts. Genetic deletion of neuronal IL-17Ra from the mouse mPFC—an integral structure for threat interpretations—recapitulated the behavioral changes observed in $\gamma\delta$ T cell-deficient mice and supported a direct effect of IL-17a in neurons. Loss of endogenous IL-17a signaling revealed more than 300 regulated genes in mPFC neurons by sNuc-Seq, many of them enriched in processes involving GABA–benzodiazepine activity, the prototypical pathway for anxiolytic drugs. Further studies are necessary to fully address whether these transcriptional changes may have a causal connection with the behavioral readouts, and which are the downstream pathways following the basal IL-17a signaling in neurons.

Unexpectedly, ablation of neuronal IL-17a signaling in the primary somatosensory cortex (S1DZ) also led to similar results, possibly suggesting that anxiety readout is part of a complex behavioral phenotype observed in the absence of neuronal IL-17Ra, encompassing brain areas beyond the PFC. The complex role of IL-17Ra signaling in the brain has previously been appreciated in mouse

models of autism. While embryonic IL-17Ra signaling on S1DZ results in social impairment²¹, the same signaling during adulthood promotes sociability²⁰.

Alleviated anxiety-like behavior has previously been linked to the lack of microbiota¹⁹. Interestingly, we found that commensal-derived signals regulate the transcriptional levels of IL-17a by meningeal $\gamma\delta 17$ cells. This is in disagreement with the previously published work⁵, which may have missed the commensal participation by assessing IL-17a expression by ex vivo stimulation. Similar caveats should be noted with regard to our studies using IL-23- and IL-1R-deficient mice. It remains unclear how signals derived from commensals activate meningeal $\gamma\delta 17$ T cells and whether such activation depends on TCR signaling. Further studies are needed to address how TCR specificity and diversity could modulate meningeal immunity and host behavior.

IL-17a is highly conserved across the evolution of the vertebrate immune system, probably owing to its key role in fighting infections at barrier sites. Anxiety is a normal component of the emotional repertoire, aiding survival by increasing awareness while also enabling rapid responses to environmental threats¹². In the highly pathogenic ancestral environments, evolutionary conservation of tissue sentinels such as meningeal $\gamma\delta 17$ T cells may have allowed organisms to respond rapidly to environmental stresses while also adapting to additional physiological processes, such as host alertness and exposure to external threats including predators and pathogens. In the modern world, given the growing interest in the involvement

of IL-17a in neuropsychiatric conditions such as anxiety, depression and autism, our findings may shed new light on the understanding of these mechanisms and support further research on the development of new therapeutic targets.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41590-020-0776-4>.

Received: 19 June 2020; Accepted: 5 August 2020;

Published online: 14 September 2020

References

1. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat. Rev. Immunol.* **16**, 22–34 (2016).
2. Alves de Lima, K., Rustenhoven, J. & Kipnis, J. Meningeal immunity and its function in maintenance of the central nervous system in health and disease. *Annu. Rev. Immunol.* **38**, 597–620 (2020).
3. Derecki, N. C. et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. *J. Exp. Med.* **207**, 1067–1080 (2010).
4. Filiano, A. J. et al. Unexpected role of interferon- γ in regulating neuronal connectivity and social behaviour. *Nature* **535**, 425–429 (2016).
5. Ribeiro, M. et al. Meningeal $\gamma\delta$ T cell-derived IL-17 controls synaptic plasticity and short-term memory. *Sci. Immunol.* **4**, eaay5199 (2019).
6. Van Hove, H. et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. *Nat. Neurosci.* **22**, 1021–1035 (2019).
7. Vantourout, P. & Hayday, A. Six-of-the-best: unique contributions of $\gamma\delta$ T cells to immunology. *Nat. Rev. Immunol.* **13**, 88–100 (2013).
8. Zhou, Y. et al. Deletion of the γ -aminobutyric acid transporter 2 (*GAT2* and *SLC6A13*) gene in mice leads to changes in liver and brain taurine contents. *J. Biol. Chem.* **287**, 35733–35746 (2012).
9. Unutmaz, D. et al. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. *J. Immunol.* **165**, 3284–3292 (2000).
10. Kipnis, J. Multifaceted interactions between adaptive immunity and the central nervous system. *Science* **353**, 766–771 (2016).
11. Filiano, A. J., Gadani, S. P. & Kipnis, J. How and why do T cells and their derived cytokines affect the injured and healthy brain? *Nat. Rev. Neurosci.* **18**, 375–384 (2017).
12. Calhoun, G. G. & Tye, K. M. Resolving the neural circuits of anxiety. *Nat. Neurosci.* **18**, 1394–1404 (2015).
13. Griebel, G. & Holmes, A. 50 years of hurdles and hope in anxiolytic drug discovery. *Nat. Rev. Drug Discov.* **12**, 667–687 (2013).
14. Louveau, A. et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. *Nat. Neurosci.* **21**, 1380–1391 (2018).
15. Ringstad, G. & Eide, P. K. Cerebrospinal fluid tracer efflux to parasagittal dura in humans. *Nat. Commun.* **11**, 354 (2020).
16. Koenecke, C. et al. In vivo application of mAb directed against the $\gamma\delta$ TCR does not deplete but generates “invisible” $\gamma\delta$ T cells. *Eur. J. Immunol.* **39**, 372–379 (2009).
17. Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. *Nature* **523**, 337–341 (2015).
18. Nielsen, M. M., Witherden, D. A. & Havran, W. L. $\gamma\delta$ T cells in homeostasis and host defence of epithelial barrier tissues. *Nat. Rev. Immunol.* **17**, 733–745 (2017).
19. Heijtz, R. D. et al. Normal gut microbiota modulates brain development and behavior. *Proc. Natl Acad. Sci. USA* **108**, 3047–3052 (2011).
20. Reed, M. D. et al. IL-17a promotes sociability in mouse models of neurodevelopmental disorders. *Nature* **577**, 249–253 (2020).
21. Choi, G. B. et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. *Science* **351**, 933–939 (2016).
22. Kohlgruber, A. C. et al. $\gamma\delta$ T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. *Nat. Immunol.* **19**, 464–474 (2018).
23. Hu, B. et al. $\gamma\delta$ T cells and adipocyte IL-17RC control fat innervation and thermogenesis. *Nature* **578**, 610–614 (2020).
24. Chen, C. et al. IL-17 is a neuromodulator of *Caenorhabditis elegans* sensory responses. *Nature* **542**, 43–48 (2017).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2020

Methods

Mice. All mice (C57/BL/6J, *Tcrd*^{CreERT2}, Ai6, CD45.1, *Cxcr6*^{GFP}, *Tcrd*^{-/-}, *Il17a*^{-/-}, *Il1r1*^{-/-}, *Fos*^{CreERT2}, Ai14, *Il17ra*^{fl/fl} and *Syn1*^{Cre}) were either bred in house or purchased from The Jackson Laboratory. The *Il17a*^{GFP} and *Il23a*^{-/-} (Genentech) mice were kindly donated by A. Gaultier and M. Salmon, respectively. A. Kuan kindly donated the *Ccr2*^{CreERT2}:Ai6 and *Ccr2*^{RFP/RFP} strains. For the microbiota experiments, germ-free and specific pathogen-free C57/BL6/J animals were purchased from Taconic and used immediately after arrival. When purchased from JAX, animals were maintained for at least 1 week to habituate before experimentation. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Virginia (UVA) and adhered to ethical consideration in animal research.

Human samples. Autopsy specimens of adult human dura and arachnoid ($n=2$) were obtained from the Department of Pathology at the UVA. All samples were from consenting patients who gave no restriction to the use of their body for research and teaching (through UVA's Institutional Review Board for Health Sciences Research). Patients had no previous record of neurological diseases and samples were processed as soon as 4 h after patient death. Samples were physically minced before digestion and processed as described in the section 'Flow cytometry'. Cell surface staining was performed at 4 °C for 30 min. The list of antibodies is shown in Supplementary Table 1 and antibodies were diluted according to the manufacturer's instructions.

Antibiotic treatment. For ablation of commensal bacteria, an antibiotic cocktail of 1 g l⁻¹ each of ampicillin sodium salt (Sigma–Aldrich), neomycin trisulfate salt hydrate (Sigma–Aldrich) and metronidazole (Sigma–Aldrich) and 0.5 g l⁻¹ vancomycin hydrochloride (Alvogen) was used over 14 d, as previously described²⁵. Antibiotics were replaced into the drinking water every other day. Antibiotic activity was confirmed on day 14 by changes in cecum size due to bacterial death.

Intra-cisterna magna injections. Mice were anesthetized by intraperitoneal injection of a mixed solution of ketamine (100 mg kg⁻¹) and xylazine (10 mg kg⁻¹) in saline. The skin of the neck was shaved and cleaned with iodine and 70% ethanol, ophthalmic solution was placed on the eyes to prevent drying and the head of the mouse was secured in a stereotaxic frame. After making a skin incision, the muscle layers were retracted and the cisterna magna was exposed. Using a Hamilton syringe (coupled to a 33-gauge needle), 5 µl of artificial CSF (aCSF; Harvard Apparatus) containing cytokine or antibody was injected into the CSF-filled cisterna magna compartment. For meningeal $\gamma\delta$ T cell functional depletion, 2.5 µg anti-TCR $\gamma\delta$ (UC7-13D5; BioXCell) or isotype control (polyclonal Armenian hamster IgG; BioXCell) was injected. For IL-17a blockade, 2.5 µg anti-IL-17a (17F3; BioXCell) or isotype control (MOPC-21; BioXCell) was used. For IL-17a injections into *Tcrd*^{-/-} animals, mice were deeply anesthetized with isoflurane, and 25 ng IL-17a (eBioscience) or aCSF was injected 3 h before the behavior task. For the aryl hydrocarbon receptor stimulation, 5 µl FICZ (10 ng; Tocris; 5304) was injected 24 h before euthanasia. After injections, the neck skin was then sutured and mice were subcutaneously injected with ketoprofen (2 mg kg⁻¹) and allowed to recover on a heat pad until fully awake.

Parabiosis. Mice were anesthetized to full muscle relaxation with xylazine and ketamine by intraperitoneal injection. The corresponding lateral aspect of each mouse was shaved, and an incision was made from the olecranon to the knee joint of each mouse, bluntly dissecting the subcutaneous fascia to create 0.5 cm of free skin on each side of the incision. The olecranon and knee joints were attached by an absorbable 5-0 Vicryl suture. The dermises of the parabiotic partners were pushed together (excluding epidermal layers in the junction of the dermis) and closed with sutures. Post-surgery, systemic analgesics (2–5 mg kg⁻¹ ketoprofen every 24 h) were administered simultaneously with antibiotics (Baytril; Bayer). All parabiotic pairs were sacrificed after 4 weeks, disjoined and separately perfused.

PFC AAV delivery. *Il17ra*^{fl/fl} or C57BL/6 (wild-type) mice were anesthetized by intraperitoneal injection of ketamine and xylazine in saline and the head was secured in a stereotaxic frame. An incision was made in the skin to expose the skull and a hole was drilled bilateral at 2.22 mm in the anterior–posterior axis and 0.4 mm in the medial–lateral axis relative to the bregma. Then, using a Hamilton syringe (coupled to a 33-gauge needle) placed at 2.5 mm in the dorsal–ventral axis (relative to the bregma), 0.5 µl aCSF of AAV9-hSyn1-eGFP-Cre (purchased from Addgene) was injected at a rate of 0.5 µl min⁻¹ into the brain parenchyma. The scalp skin was sutured, after which the mice were subcutaneously injected with ketoprofen (2 mg kg⁻¹) and allowed to recover on a heat pad until further experiments.

Behavior. Experimental groups were blinded and randomly assigned before the start of experimentation and remained blinded until all data were collected. Mice were housed under standard 12 h light/dark cycle conditions in rooms equipped with control for temperature and humidity. Most of our behavior studies were performed on male mice, and our key findings were also tested in female mice. We never mixed the results from different sexes. Unless stated otherwise, mice

were tested at 8–10 weeks of age. Sample sizes were chosen on the basis of a power analysis using estimates from previously published experiments. For cohorts tested with multiple behavioral assays, the elevated plus maze was performed first and then followed by the open field before any other test. Before all experiments, mice were transported to the behavior room and given at least 30 min to habituate. All behavioral testing was conducted during daylight hours. More details regarding the behavior experiments are described in Supplementary Table 2.

Elevated plus maze. Briefly, mice were transported to the testing room and habituated for at least 30 min. The room was maintained in dim light and a white noise generator was used to mitigate any unforeseen noises. The plus maze consisted of four arms (two open without walls and two enclosed by 20-cm-high walls) that were 35 cm long and 6 cm wide (Med Associates). Each arm of the maze was elevated 75 cm off the floor. For the behavior analysis, mice were placed into the center hub and allowed to explore the plus maze for 5 min. Video tracking software (TopScan (CleverSys) and EthoVision (Noldus)) were used to quantify the time spent in the open arms.

Open field. Animals were previously habituated for at least 30 min in the testing room and then placed into the open field (35 cm × 35 cm) to explore for 15 min. The total distance and time spent in the center (23 cm × 23 cm) were quantified using video tracking software (TopScan (CleverSys) and EthoVision (Noldus)).

Novel location recognition test. The novel location recognition test was performed as described in ref. 26. Mice were first habituated to the apparatus for 15 min. After the habituation phase, two plastic objects (with different colors and shapes) were placed in the arena. Mice were then placed in the arena again and allowed to explore for 10 min. The next day, one of the objects had switched location (novel) and the mice were allowed to explore the arena for another 10 min. The time spent exploring the objects in the familiar and novel locations was measured using a video tracking software (TopScan; CleverSys). The object location preference (the percentage of time with the object) was calculated as the exploration time of the objects in the familiar or novel location divided by the total exploration time.

Contextual fear conditioning test. Contextual fear conditioning was performed as previously described with minor modifications²⁶. Briefly, on day 1, mice were placed in the conditioning chamber and allowed to habituate for 3 min. Then, mice received three pairs of cue aversive stimuli, consisting of tone (18 s; 5 kHz; 75 dB)–shock (2 s; 0.5 mA) pairings, separated by an interval of 40 s (total of 3 min). On day 2, mice were tested and scored for conditioned fear of the training context for 3 min (context trial), in the absence of the cue stimulus. After 2 h, animals were presented to a novel context and allowed to habituate for 3 min. After the habituation phase, they received a continuous cue stimulus (tone) for an additional 3 min (cued trial). Mouse behavior was recorded by a digital video camera mounted above the conditioning chamber and freezing was manually scored by a blinded experimenter using the EthoLog version 2.2 software. The parameters analyzed included the percentage of time freezing during the 3 min of the context test and the last 3 min of the cued test.

Three-chamber sociability assay. The three-chamber sociability test was conducted as previously published with minor changes⁴. Test mice were placed in the center chamber and allowed to explore for 10 min (habituation phase). After habituation, animals were returned to the center chamber. A C57BL/6J mouse (8–10 weeks old) was placed under one cup and an object was placed under the other. Tested mice were allowed to explore for an additional 15 min (social phase) and video tracking (TopScan; CleverSys) was used to quantify the time spent around each target. The percentage of interaction was calculated as the exploration time in the mouse (social) or object (inanimate) chamber divided by the total exploration time.

Foraging behavior. The foraging behavior was conducted as previously described with minor changes²⁷. Briefly, mice were first habituated with sand (Jurassic play sand; Jurassic Sands) and seeds (Whole millet; Living Whole Foods) for 2 d in their home cage. For testing, mice were habituated into the behavior room and placed into the testing cage attached to the arena 15 min before testing. At the start of testing, the testing cage was attached to the arena via the tunnel. The mouse had access to the arena and video recording started for the exploration phase. Mouse behavior was recorded continuously during the 30 min exploration phase trial. After completing the exploration phase, the mouse was transferred to a holding cage and 4 h later tested for the foraging phase. Video recording was also performed for an additional 30 min. Between each exploration and foraging phase trial, the entire arena, including the walls, platform, tunnel and steel pots, was wiped clean with 70% ethanol.

Unpredictable chronic mild stress. Briefly, mice were given daily unpredictable acute and overnight stresses for 8 weeks. Physical restraint, loud white noise, crowded housing and strobe lighting were used as acute stressors. Mice were additionally submitted to overnight lights being on during the dark cycle, wet bedding, cage tilting and frequent cage changing.

Acute stress. Acute stress was induced using the electric shock model. Mice were individually placed in a chamber with a grid floor connected to a shock generator. The mice were exposed to a 3-s foot shock (0.6 mA) five times during 120 s randomly for seven consecutive days. For the control group, mice were placed in the chamber at the same time without foot shock.

EAE induction. For active induction of EAE, mice were immunized by subcutaneous injection of 200 µg MOG_{35–55} (CSBio) in Complete Freund's Adjuvant (Sigma–Aldrich) and received 200 ng pertussis toxin (List Biological Laboratories) intraperitoneally on days 0 and 2.

Meninges dissection and immunohistochemistry. Mice were given a lethal dose of anesthetics by intraperitoneal euthasol (10% vol/vol) and transcardially perfused with ice-cold 0.025% (wt/vol) heparin in phosphate-buffered saline (PBS). Mice were decapitated immediately posterior to the occipital bone, and overlying skin and muscle were removed from the skull. The mandibles and skull rostral to the maxillae were removed and the remaining skull was drop fixed in 4% paraformaldehyde (PFA) at 4°C for 24 h. The skull cap was then removed with fine surgical scissors by clockwise incisions, beginning and ending at the occipital bone, and was stored in 1× PBS with 0.02% azide. The brain was removed, placed in 4% PFA for an additional 24 h, then transferred to 30% sucrose in PBS until it had completely sunk (24–48 h). Brains were embedded in O.C.T. (Fisher Healthcare), rapidly frozen over dry ice and stored at –20°C. Coronal cryosections (40 µm) were cut using a cryostat (Leica) and free-floating sections were stored in PBS with 0.02% azide until use. Meningeal whole mounts were prepared by careful peeling from the skull cap using fine surgical forceps as previously described¹⁷ and stored in 1× PBS with 0.02% azide. Free-floating brain sections and meningeal whole mounts were blocked and permeabilized for 1 h at room temperature in 24-well plates with constant agitation using block/stain buffer (PBS with 0.2% Triton X-100 and 2% chicken serum). Sections were then incubated with primary antibodies in block/stain buffer at 4°C for 24 h with agitation, washed three times in PBS with 0.2% triton (PBS-T) and incubated with secondary antibodies (1:500 dilution) for 2 h at room temperature with gentle agitation. Sections were washed once in PBS-T and incubated with 4',6-diamidino-2-phenylindole (DAPI; 1 µg ml⁻¹) in PBS-T. Sections were mounted on SuperFrost Plus slides (Thermo Scientific) and coverslipped with Aqua-Mount (Lerner). The list of antibodies used and their catalog numbers are presented in Supplementary Table 1.

In situ hybridization. Brains were extracted and embedded in O.C.T. compound on dry ice and sections were cut at 16 µm thickness on a cryostat. In situ hybridizations were performed using the RNAscope Multiplex Fluorescent Assay V2 accordingly to the manufacturer's recommendations (323100; Advanced Cell Diagnostics). For *Il17ra* staining, we used the probe Mm-*Il17ra*-C1 (403741; Advanced Cell Diagnostics). The probe DapB (310043; Advanced Cell Diagnostics) was used as a negative control. For detection of glutamatergic and GABAergic populations, we used the probes Mm-*Slc17a7*-C2 (416631) and Mm-*Gad2*-C3 (439371), respectively (both from Advanced Cell Diagnostics).

Confocal microscopy. Meningeal whole mounts or brain slices were acquired with a Leica TCS SP8 confocal system (Leica Microsystems) using the LAS AF Software. Quantitative analysis of c-Fos imaging measurements was performed blinded with the FIJI package for ImageJ, using the cell counter. For the AAV-delivered experiments, IL-17Ra⁺ cells were quantified in FIJI. Cells were segmented in max-projected images using the StarDist plugin²⁸. Protein punctae were segmented with the Analyze Particles function after three-dimensional difference-of-Gaussian filtering with the CLIJ2 plugin²⁹ and thresholding. The numbers of puncta were counted for each segmented cell, and further processing of the data was performed in R. For all measurements, five sites per brain/meninges were collected, and the results were averaged to generate the value utilized for a single mouse.

c-Fos reporter activation. 4-Hydroxytamoxifen (Sigma–Aldrich; H6278) was dissolved at 20 mg ml⁻¹ in ethanol by shaking at 37°C for 15 min and was then aliquoted and stored at –20°C for up to several weeks. Before use, 4-OHT was re-dissolved in ethanol by shaking at 37°C for 15 min. Chen oil (1:4 mixture of castor oil (both from Sigma–Aldrich) was added to give a final concentration of 10 mg ml⁻¹ 4-OHT, and the ethanol was evaporated by vacuum under centrifugation. To determine the number of TRAPed cells, *Fos*^{CreERT2}; Ai14 mice were injected intra-cisterna magna with 25 ng IL-17a (eBioscience) and 1 h later were given an intraperitoneal injection of 10 mg kg⁻¹ 4-OHT. Mice were killed and perfused 7 d after injection for immunohistochemistry analysis.

Flow cytometry. Mice were given a lethal dose of 10% (vol/vol) euthasol in saline (intraperitoneally) and transcardially perfused with ice-cold 0.025% (wt/vol) heparin in PBS. Meninges were dissected as previously described and digested for 15 min at 37°C with 1.4 U ml⁻¹ Collagenase VIII (Sigma–Aldrich) and 35 U ml⁻¹ DNase I (Sigma–Aldrich) in Iscove's modified Dulbecco's media (Sigma–Aldrich). Following the digestion step, the tissue was gently pressed through 70 µm nylon mesh cell strainers. Cells were then centrifuged at 450g at 4°C for 4 min. The cell pellets were resuspended in ice-cold FACS buffer (2 mM EDTA, 25 mM HEPES

and 1% bovine serum albumin (BSA) in 1× PBS) and stained for extracellular markers at 1:300 dilution. The list of flow antibodies used is presented in Supplementary Table 1. Samples were run on a flow cytometer Gallios (Beckman Coulter) then analyzed using FlowJo software version 10 (Treestar).

Intracellular staining. Intracellular staining was performed as described³⁰. Briefly, single-cell isolates from meninges were stimulated for 4 h in Iscove's modified Dulbecco's media (supplemented with 1× non-essential amino acids, 50 U ml⁻¹ penicillin, 50 µg ml⁻¹ streptomycin, 50 µM β-mercaptoethanol, 1 mM sodium pyruvate and 10% FBS; all from Gibco) with PMA/ionomycin (Cell Stimulation Cocktail; eBioscience) and 1× brefeldin A (eBioscience) at 37°C before extracellular staining as stated above. Cells were then permeabilized with a Foxp3/Transcription Factor Staining Buffer Set (eBioscience) and stained for 30 min at 4°C. All antibodies used were diluted at 1:250.

Labeling of the vascular compartment. To assess the abluminal localization of the sinusal γδ T cells, mice were injected intravenously with 2.5 µg eFluor 450-conjugated anti-CD45 antibody (eBioscience; clone 30-F11) 3 min before euthanasia.

In vivo cell labeling and EdU detection. Mice received daily intraperitoneal injections of 10 mg kg⁻¹ EdU (Carbosynth; 61135-33-9) during three consecutive days. EdU detection was performed using the Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit and Click-iT Plus EdU Cell Proliferation Kit for Imaging Alexa Fluor 647 dye, following the manufacturer's instructions.

Mass cytometry. Single-cell suspensions of dural meninges were stained with the metal-conjugated antibodies and reagents summarized in Supplementary Table 3. Concentrations for each antibody used in the panel were optimized on meningeal tissue, titrated and optimal concentrations used in the panel. If not otherwise stated, cells were washed and stained in Maxpar buffers (Fluidigm). The entire meninges were transferred to a 96-well plate and incubated with 5 µM cisplatin (Cell-ID; Fluidigm; diluted in Maxpar PBS) for 5 min at room temperature. After two washes with Maxpar Cell Staining Buffer (MP CSB), cells were pre-incubated with anti-mouse CD16/32 to block Fc receptors for 15 min on ice. An equal volume of a cocktail of fixation-sensitive markers and fluorescent antibodies was added and the samples were incubated on ice for an additional 25 min. Following two washes with Maxpar CSB, cells were fixed in 1.6% EM-grade PFA (Electron Microscopy) in Maxpar PBS for 10 min at room temperature. Individual samples were barcoded with the Cell-ID 20-Plex barcoding kit according to the manufacturer's instructions (Fluidigm), and combined and multiplexed samples were stained with the remaining surface markers of the panel for 30 min on ice. Intracellular staining of markers within the nucleus was performed using the Maxpar Nuclear Antigen Staining Buffer Set (Fluidigm) for 30 min on ice. Following two washes, cells were incubated in 1:2,000 dilution of intercalator-Ir (in Maxpar Fix and Perm Buffer) overnight at 4°C. Before acquisition on a Helios mass cytometer, samples were washed with Maxpar Fix and Perm Buffer, Maxpar water and Maxpar Cell acquisition solution. The stained and intercalated cell pellet was resuspended to a concentration of ~10⁶ cells per ml in Maxpar Cell acquisition solution and a five-element bead standard was added.

Pre-processing of mass cytometry data. Samples were debarcoded using the Zunder laboratory single-cell debarcoder (<https://github.com/zunderlab/single-cell-debarcoder>) in MATLAB, and files were uploaded in Cytobank. Raw data were manually gated to exclude debris, doublets, dead cells, normalization beads and live single CD45 cell events from Cytobank.

Automated population identification in high-dimensional data analysis. Gated Flow Cytometry Standard files were read into R and expression values for each marker were transformed using the arcsinh transformation. Cells were further analyzed as previously described in the Robinson workflow (https://bioconductor.riken.jp/packages/3.2/bioc/vignettes/cytofkit/inst/doc/cytofkit_example.html) using the Rphenograph clustering algorithm with all markers from the panel as input features³¹. Expert-guided definition of cell clusters was done based on heatmaps of median expression values of the initial Rphenograph nodes. Differential expression of specific markers between the identified clusters of CD4⁺CD8⁺ and γδ T cells was tested using a pairwise Wilcoxon rank-sum test with Benjamini–Hochberg post-hoc adjustments.

Cell sorting and scRNA-Seq analysis. P7 or adult (8-week-old) C57BL/6 mice were given a lethal dose of 10% (vol/vol) euthasol in saline (intraperitoneally) and transcardially perfused with ice-cold 0.025% (wt/vol) heparin in PBS. Meninges and spleens were harvested and physically minced before being digested, as previously described. A single-cell suspension was obtained and immunostained with LIVE/DEAD Fixable Aqua Dead (eBioscience), anti-CD45 APC (BD Biosciences), anti-TCR γδ PE (BioLegend) and anti-TCR β FITC (BioLegend) using the BD Influx Cell Sorter (BD Biosciences) and sorted as CD45⁺TCR γδ⁺TCR β^{neg} live cells. Cells were encapsulated in one lane of a 10× Chromium instrument, and libraries were constructed with a Single Cell 3' Reagent Kit

(V2 Chemistry) following the manufacturer's instructions. Libraries were then sequenced on the NextSeq 500 platform.

Nuclei isolation and sorting. Wild-type mice ($n = 3$) were sacrificed and transcardially perfused with ice-cold aCSF. The brains were collected and 400 μM coronal sections were prepared using a vibratome. The dentate gyrus was dissected from the coronal sections and placed in 1 \times Hanks' balanced salt solution. For the mPFC isolation, *Syn1^{Cre}* ($n = 4$), *Il17ra^{fl/fl}* ($n = 4$) and *Syn1^{Cre}Il17ra^{fl/fl}* ($n = 4$) mice were first tested in the elevated plus maze task and 1 h later sacrificed and transcardially perfused with ice-cold PBS with heparin. The brains were collected and the mPFC was isolated as prescribed by ref. ³². Briefly, coronal sections were made using a brain slicer matrix and a sharp razor blade. Sections were made until the anterior commissure was visible and subsequent sections were prepared that contained the darker area in the middle that represents the mPFC. The mPFC was then dissected from these sections and placed in 1 \times Hanks' balanced salt solution on ice. The dentate gyrus and mPFC sections were transferred in the nuclei isolation medium (0.25 M sucrose, 25 mM KCl, 5 mM MgCl₂, 10 mM Tris-Cl (pH 7.4), 100 μM dithiothreitol and 1 \times protease inhibitor (Roche) in PBS) and triturated using a wide-bore pipette. The triturated tissue was gently homogenized using a Dounce tissue grinder. The homogenized tissue was filtered through a 70- μM nylon mesh cell strainer and centrifuged at 1,000g for 8 min at 4°C. The supernatant was removed carefully. The isolated nuclei were washed and resuspended in 1% BSA in PBS. They were subsequently stained with Hoechst 33342 (1:1,000) and anti-NeuN Alexa Fluor 647 (1:500). The stained nuclei were washed with 1% BSA, pelleted and resuspended in 1% BSA in PBS. They were sorted using the Influx Cell Sorter (Beckman Dickinson) available at the UVA Flow Cytometry Core Facility. Intact nuclei were gated on the basis of positive Hoechst 33342 staining. From that population, singlets were isolated following gating on forward scatter height versus forward scatter width and on forward scatter height versus side scatter height. The NeuN⁺ nuclei were then sorted from that population into 1.5 ml LoBind tubes containing 400 μl 0.04% non-acetylated BSA in PBS. After sorting, the nuclei were pelleted and resuspended in 10–20 μl 0.04% non-acetylated BSA in PBS for the preparation of single-nuclei libraries using the 10 \times Genomics Platform.

Single-cell data pre-processing. Base call files were converted to Cell Ranger-compatible FASTQ files using the Illumina bcl2fastq2 software. Reads were then aligned to the mm10 transcriptome using the Cell Ranger software pipeline (version 3.0.2) provided by 10 \times Genomics, specifically the count function with the pre-mRNA reference used for nuclei. The resulting raw gene by cell matrices of unique molecular identifier counts for each sample, adult meningeal $\gamma\delta$ T cells, P7 meningeal $\gamma\delta$ T cells, adult splenic $\gamma\delta$ T cells and P7 splenic $\gamma\delta$ T cells were read into R using the read10xCounts function from the DropletUtils package and filtered to remove barcodes that did not show significant deviations from the ambient RNA profile using the EmptyDrops method^{33,34}. The count-filtered matrices were then merged by gene symbol to create one matrix with all $\gamma\delta$ T cells. Similarly, neuronal nuclei isolated from the PFC were analyzed together, and neuronal nuclei isolated from the dentate gyrus comprised a third separate analysis. For each dataset, filtering was applied to remove low-quality cells by excluding those with low unique molecular identifier counts, low numbers of unique genes or high levels of mitochondrial gene expression. Expression values for the remaining cells were then normalized using the scran and scater packages, and the resulting log₂ values were transformed to the natural log scale for compatibility with the Seurat (version 3.0) pipeline^{35–37}.

Dimensionality reduction and clustering of $\gamma\delta$ T cells. The filtered and normalized matrix was used as input to the Seurat pipeline, and after a preliminary exploration of the dataset, one population of macrophages was identified based on the expression of *H2.Aa*, *H2.Ab1*, *Ly6d* and *Cd79a*. After exclusion of this population, expression values for the remaining 1,041 cells were scaled across each gene and highly variable genes were identified using the FindVariableFeatures function with the variance-stabilizing transformation method. The top 2,000 highly variable genes were filtered to remove ribosomal and Riken genes and the remaining genes were used for principal component analysis. Statistical significance for the first 20 components was calculated using the jackstraw test and the first eight components were used for t-distributed stochastic neighbor embedding analysis, UMAP and clustering. Shared nearest neighbor clustering optimized with the Louvain algorithm, as implemented by the Seurat FindNeighbors and FindClusters functions, resulted in ten clusters and a modularity score of 0.8313.

Analysis of neuronal nuclei. The filtered and normalized matrices of normalized counts were used to create Seurat objects for each region (mPFC and dentate gyrus). Each dataset was then scaled across all features to remove the effects of sequencing depth and mitochondrial gene expression. Variable genes for each dataset were identified using the variance-stabilizing transformation method and the first 50 principal components were computed for each dataset using the top 2,000 highly variable genes. The numbers of principal components used for shared nearest neighbor clustering and for projection into two dimensions with

the UMAP algorithm were determined based on significance as evaluated with the jackstraw test, as well as based on the percentage of variance in the dataset explained by each component. Clusters were then identified as GABAergic or glutamatergic based on their expression of canonical marker genes such as *Gad1*, *Gad2*, *Slc17a7* and *Slc17a6*. In the dentate gyrus, three clusters of either *Aqp4*- or *Olig2*-expressing cells were removed to prevent potential contamination by glial populations and the remaining cells were reanalyzed using the same process as described. In the PFC, glutamatergic clusters were further categorized into cortical layers using genes previously described in the literature, such as *Cux1*, *Rasgrf2*, *Etv1*, *Cdh13* and *Bcl11b*. Descriptive markers for each cluster were identified using the FindAllMarkers function with the Wilcoxon test and Bonferroni corrections to test genes with average log[fold changes] of at least 0.5 in the cluster of interest compared with all other clusters. To test for differences between samples (*Syn1^{Cre}*, *Il17ra^{fl/fl}* and *Syn1^{Cre}Il17ra^{fl/fl}*), the log[fold change] threshold for testing was set to 0.1 and only genes expressed in a minimum of 10% of cells were tested. For functional enrichment, the clusterProfiler package was used to enrich the sets of genes that were significantly up- or downregulated in both the comparison of *Syn1^{Cre}Il17ra^{fl/fl}* with the *Syn1^{Cre}* control and the comparison of *Syn1^{Cre}Il17ra^{fl/fl}* with the *Il17ra^{fl/fl}* control for Gene Ontology terms or Kyoto Encyclopedia of Genes and Genomes pathways.

Differential expression. For all differential expression testing, the Wilcoxon rank-sum test was used with the Bonferroni correction using the FindMarkers function. Unless otherwise stated previously, only genes showing a minimum log[fold change] of 0.1 between groups were tested for significance.

Pathway enrichment. Fisher's exact test was used to determine significantly enriched Gene Ontology biological processes, cellular components and molecular functions for the sets of significantly DEGs (adjusted P value (P_{adj}) < 0.05) for each comparison using the enrichGO function from the ClusterProfiler package^{38,39}. For each enrichment analysis, the gene set size was set to a range of 10–500 genes and the Benjamini–Hochberg adjustment was used to correct for false discovery rates. The enrichment results for meningeal $\gamma\delta$ T cells (adult versus pup) were simplified using the simplify function from the ClusterProfiler package to reduce redundant terms before filtering the top ten terms by significance for visualization. Enrichment results were visualized using the DOSE heatmap and dotplot functions. For enriched pathways visualized in the mPFC neuronal nuclei dataset, terms were chosen based on descriptions containing the following words or phrases: serotonin, kynurenine, ephrin, dopamine, calcium ion transport, calcium channel, neurotransmitter, NMDA, AMPA, GABA, benzodiazepine, postsynaptic density, postsynaptic membrane, axon and potassium.

Whole-patch clamp recording. Studies were conducted in collaboration with AfaSci. C57BL/6 mice (Charles River; P9 to P58 days) were used in the experiments. Recombinant IL-17a (eBioscience) was prepared in PBS at a stock concentration of 0.1 mg ml⁻¹. Aliquots of the stock solutions were frozen at –20°C until use. aCSF was prepared and contained 124 mM NaCl, 2.5 mM KCl, 2.4 mM CaCl₂, 1.2 mM KH₂PO₄, 26 mM NaHCO₃, 10 mM glucose and 1.3 mM MgSO₄. aCSF was bubbled with 5% CO₂ and 95% O₂ for at least 15 min before use and continuously throughout use. For brain slice preparation, aCSF was stored at –20°C for 30 min until becoming a partially frozen slush. Mice were deeply anesthetized with isoflurane and then decapitated. The brains were quickly excised and transferred to the aCSF slush preparation and were allowed to chill for 1 min. The brains were then transferred to a filter paper soaked with ice-cold aCSF where the caudal region of the brain was removed by a coronal cut in order to attach, using super glue, the remainder of the brain flat on the specimen holding plate of the vibrating blade microtome (Leica VT1000S). The brains were bathed in ice-cold/slush aCSF while preparing the slices. Coronal slices of the rostral brains were cut with a thickness of 250 μm and transferred to an elevated mesh platform inside a glass beaker filled with continuously bubbled aCSF at a temperature of 20–25°C. Slices were cut until the appearance of the genu corpus callosum connecting both hemispheres of the brain. Experiments were performed two to four layers before the final slice made in the mPFC. The slices were allowed to rest for at least 1 h before performing electrophysiological recordings. Whole-cell responses were recorded using a MultiClamp 700B (Molecular Devices) amplifier and head stage and low-pass filtered at 10 kHz before digitization using a Digidata 1440 data acquisition system (Molecular Devices). Data were stored on a PC running pCLAMP software (version 10.4; Molecular Devices). Patch pipettes were fabricated from 1.5 mm outside diameter borosilicate capillary glass (Warner Instruments) using a micropipette puller (Sutter Instrument; model P-87) and had tip resistances of 4–6 M Ω . The series resistance for all recordings ranged from 10–30 M Ω . Capacitance transients and series resistance errors were compensated for (70%) using the amplifier circuitry for voltage clamp recordings. For spontaneous action potential, evoked action potential and sEPSC recordings, the intracellular solution contained 140 mM K-gluconate, 10 mM HEPES, 11 mM EGTA, 0.5 mM CaCl₂, 0.5 mM MgCl₂, 0.25 mM NaGTP and 2 mM MgATP. The internal solution was brought to pH 7.4 and had a liquid junction potential of 14.5 mV in the bathing solution. For sIPSC recordings, the intracellular solution contained 140 mM Cs-gluconate, 10 mM HEPES, 11 mM EGTA, 1 mM CaCl₂ and

1 mM MgCl₂. The internal solution was brought to pH 7.4 and had a liquid junction potential of 14.7 in the bathing solution. Brain slices in the recording chamber that was mounted on a phase-contrast microscope (Olympus BX51WI) were perfused with aCSF (1–2 ml min⁻¹) continuously bubbled with 5% CO₂ and 95% O₂. Cells were identified using bright-field phase-contrast microscopy under the surface of the slices. Cells were patched in the whole-cell configuration and were held at -65 or -80 mV for spontaneous or evoked action potential recordings, respectively, in the current clamp configuration, as well as -90 or -15 mV for sEPSC and sIPSC recordings, respectively, in the voltage clamp configuration. sEPSCs were observed as downward spikes that could be blocked by the addition of 30 μM DNQX. sIPSCs were observed as upward spikes that could be blocked by the addition of 10 μM bicuculline. Data reduction for sampling intervals of 200 μs, as well as low-pass filtering, was used to reduce noise in raw traces of sEPSC and sIPSC recordings. sEPSC and sIPSC events were measured using Clampfit's Template Search program. Templates were created by selecting five to ten events. EPSC and IPSC events were scored and manually verified. For each set of data (that is, control and treatment at a particular concentration in the same cell), the same template and matching threshold were used for analysis. For tests with IL-17a, working concentrations (1, 10 and 100 ng ml⁻¹) were freshly made up in aCSF. Control spontaneous action potentials, sEPSCs and sIPSCs were recorded for 5–10 min and drug solutions were applied for 20–25 min. The final 5 min of control application and 5 min of IL-17a application after a minimum of 15 min application were analyzed for spontaneous action potential, sEPSC and sIPSC parameters. For evoked action potentials, a current injection step protocol (-40, 0, 40, 80, 120, 160 and 200 pA; 500 ms) was run before and after 20 min IL-17a application. Analysis was performed using Clampfit 10.4 and Clampfit 10.7.

Statistical analysis. One-way analysis of variance (ANOVA) with appropriate multiple comparisons tests was used to compare three independent groups. Two-group comparisons were made using two-tailed unpaired Student's *t*-test. For comparisons of multiple factors, two-way ANOVA with appropriate multiple comparisons tests was used. Statistical analysis (data are always presented as means ± s.e.m.) was performed using Prism 8.0 (GraphPad Software).

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

FASTQ files and quantified gene counts for single-cell sequencing are available from the Gene Expression Omnibus under accession number [GSE147262](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147262).

References

- Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. *Cell Host Microbe* **4**, 337–349 (2008).
- Da Mesquita, S. et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. *Nature* **560**, 185–191 (2018).
- Stacher Hörndli, C. N. et al. Complex economic behavior patterns are constructed from finite, genetically controlled modules of behavior. *Cell Rep.* **28**, 1814–1829.e6 (2019).
- Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. in *Medical Image Computing and Computer Assisted Intervention – MICCAI 2018* Vol. 11071 (eds Frangi, A. F. et al.) 265–273 (Springer International Publishing, 2018).
- Haase, R. et al. CLIJ: GPU-accelerated image processing for everyone. *Nat. Methods* **17**, 5–6 (2020).
- De Lima, K. A. et al. TGFβ1 signaling sustains aryl hydrocarbon receptor (AHR) expression and restrains the pathogenic potential of T_H17 cells by an AHR-independent mechanism. *Cell Death Dis.* **9**, 1130 (2018).
- Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. *F1000Res.* **6**, 748 (2019).
- Spijker, S., Faliagkas, L. & Rao-Ruiz, P. in *Neuroproteomics* Vol. 146 (ed. Li, K. W.) 7–19 (Springer New York, 2019).
- Lun, A. T. L. et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. *Genome Biol.* **20**, 63 (2019).
- Griffiths, J. A., Richard, A. C., Bach, K., Lun, A. T. L. & Marioni, J. C. Detection and removal of barcode swapping in single-cell RNA-seq data. *Nat. Commun.* **9**, 2667 (2018).
- Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. *F1000Res.* **5**, 2122 (2016).
- McCarthy, D. J., Campbell, K. R., Lun, A. T. L. & Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics* **33**, 1179–1186 (2017).
- Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**, 411–420 (2018).
- Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS Integr. Biol.* **16**, 284–287 (2012).
- Yu, G., Wang, L.-G., Yan, G.-R. & He, Q.-Y. DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. *Bioinformatics* **31**, 608–609 (2015).

Acknowledgements

We thank S. Smith for editing the manuscript, J. Sokolowski for help with the collection of human samples and M. Beenhaker for help with interpreting the electrophysiology studies. We thank all members of the Kipnis laboratory and members of the Center for Brain Immunology and Glia (BIG) for valuable comments during multiple discussions of this work. We also thank the UVA Flow Cytometry Core for help with cell sorting, the Genome Analysis and Technology Core for help with library preparation and sequencing, and J. Graham from the Virginia Commonwealth University School of Nursing for performing the Meso Scale Discovery assay. This work was supported by grants from the National Institutes of Health (MH108156, AT010416 and AG034113) to J.K.

Author contributions

K.A.d.L. designed and performed the experiments, analyzed and interpreted the data and wrote the manuscript. M.W. analyzed the scRNA-Seq raw data and provided intellectual contributions. J.R. helped with the immunohistochemistry studies and provided intellectual contributions. S.D.M. assisted with the behavior experiments and provided intellectual contributions. A.E.S. helped with the sNuc-Seq experiments and carried out the TRAP2 experiments. I.S. performed the surgeries and animal injections. G.C.M. helped with the flow cytometry experiments. T.M. helped with the immunohistochemistry studies. W.B. assisted with the experimental procedures. Z.P. helped with the foraging behavior experiments. M.B.L. provided the human tissue samples. X.S.X. and W.S.C. performed the electrophysiology studies. J.H. helped with the CyTOF experiments. J.K. provided intellectual contribution, oversaw data analysis and interpretation and wrote the manuscript.

Competing interests

J.K. is a member of a scientific advisory group for PureTech Health.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41590-020-0776-4>.

Supplementary information is available for this paper at <https://doi.org/10.1038/s41590-020-0776-4>.

Correspondence and requests for materials should be addressed to K.A. or J.K.


Reprints and permissions information is available at www.nature.com/reprints.

Editor recognition statement Zoltan Fehervari was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.




Extended Data Fig. 1 | See next page for caption.

Extended Data Fig. 1 | Meningeal $\gamma\delta$ 17T cells are long-lived cells with low proliferative capacity in steady state. **a**, Representative contour plot and histogram of the frequency of meningeal TCR β - or TCR $\gamma\delta$ - expressing cells on the double negative (DN, CD4^{neg}CD8^{neg}) T cell population under steady state by flow cytometry. **b**, Representative histograms of CD62L, CD44, IL-1R and ROR γ t expression in meningeal and splenic $\gamma\delta$ T cells from naïve mice by flow cytometry. **c**, Representative contour plots of the intracellular staining for IL-17a, IFN γ and IL-22 in $\gamma\delta$ T cells (TCR $\gamma\delta^+$), conventional $\alpha\beta$ T cells (TCR β^+ NK1.1^{neg}) and NK T lymphocytes (TCR β^+ NK1.1⁺) isolated from spleen. **d**, Graph bars for the frequency of IL-17a, IFN γ and IL-22 for each isolated meningeal T cell subset. **d_i**, Meningeal $\gamma\delta$ T cells; **d_{ii}**, conventional $\alpha\beta$ T cells and **d_{iii}**, NK T lymphocytes (n = 5 per group). One-way ANOVA followed by Bonferroni's multiple comparisons test. **e**, Absolute number of $\gamma\delta$ T cells isolated from dura, enriched subdural meninges (eSDM), choroid plexus or brain parenchyma under homeostasis (n = 5 per group). One-way ANOVA followed by Bonferroni's multiple comparisons test. **f**, Gating strategy for the flow analysis of fresh dura sample isolated from humans. Single live cells were gated as CD45⁺ and the $\gamma\delta$ T cell frequency was determined in the CD3⁺. **f_i**, Contour plots of the frequency of $\gamma\delta$ T cells isolated from arachnoid or dura mater by flow cytometry (n = 2). **f_{ii}**, Representative dot plots of the percentage of TCR $\gamma\delta$ - or $\alpha\beta$ - expressing cells obtained from meninges during prenatal stages (around E18.5) or at 8-weeks of age (Adult). **f_{iii}**, Graph bars of the percentage and **f_{iiii}**, absolute number of $\gamma\delta$ T cells. Each pre-natal sample represents a pool of three embryos. Unpaired two-tailed t test. Data are from one single experiment. **g**, Representative flow cytometry analysis of $\gamma\delta$ T lymphocytes in the blood (top), and meninges (bottom) of CD45.1⁺ and CD45.2⁺ congenic parabiotic pairs joined for 4 weeks (n = 4 per group). **g_i**, Mean frequency of either CD45.1⁺ or CD45.2⁺ $\gamma\delta$ T cells in each parabiotic pair in the blood and meninges. **g_{ii}**, WT mice at post-natal day 14 (P14) or **g_{iii}**, adult (8 week-old) were injected daily with EdU (i.p., 10 mg/kg) and three days later the proliferating EdU⁺ cells were determined by flow cytometry. **h**, Histograms showing the EdU frequency in $\gamma\delta$ T cells and CD11b^{hi} myeloid cells isolated from meninges and spleen of P14 mice. **h_i**, Graph bars of the percentage of $\gamma\delta$ T cells or **h_{ii}**, CD11b^{hi} myeloid cells co-expressing EdU. P14 (n = 5 per group). **i**, Representative histograms of $\gamma\delta$ T lymphocytes and CD11b^{hi} myeloid cells expressing EdU in meninges and spleen of adult mice. **i_i**, Graph bars of the percentage of $\gamma\delta$ T cells and **i_{ii}**, CD11b^{hi} myeloid cells co-expressing EdU. Adult (n = 5 per group). **j**, Scheme of the experimental details used to assess the proliferation capacity of meningeal $\gamma\delta$ T cells by immunohistochemistry. P14 or adult *Tcrd*^{CreERT2}:Ai6 mice were injected daily with EdU and tamoxifen (both i.p., 10 mg/kg) and three days later the proliferation of $\gamma\delta$ T cells was determined in the whole-mount meninges by confocal microscopy. **k**, Representative images of meningeal whole-mounts isolated from P14 (left) and Adult (right) mice and stained for CD31 (blue) and EdU (red). Arrows indicate $\gamma\delta$ T cells proliferating in P14 meninges (TCR δ (ZsGreen)⁺EdU⁺). SSS, superior sagittal sinus. Scale bar, 100 μ m. Representative image of one single experiment (n = 5). Data are shown as mean \pm s.e.m. and each dot symbol represents individual mouse.




Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | Meningeal $\gamma\delta$ T cells expression profile and additional behavior paradigms using $\gamma\delta$ T cell-deficient mice. **a**, Normalized expression of *Tcr γ 6* transcripts (V γ 4 chain, Garman nomenclature) in meningeal and splenic $\gamma\delta$ T cells obtained by single cell RNA-Seq. **b**, Graph bars of the TCR V γ -usage in $\gamma\delta$ T cells. **b_i**, Meningeal and **b_{ii}**, splenic $\gamma\delta$ T cells. **b_{iii}**, Overview of V γ -chain usage (V γ 1, V γ 2, V γ 3 or others (V γ 4 or V γ 5)). **c**, Representative contour plots of the intracellular staining for IL-17a and IFN γ in $\alpha\beta$ T cells (TCR β^+ NK1.1^{neg}) and $\gamma\delta$ T lymphocytes (V γ 1, V γ 2, V γ 3–negative or positive fractions) isolated from steady state meninges. **c_{i-iv}**, Graph bars of the percentage of IL-17a– or IFN γ – producing cells in these different meningeal T cell subsets. One-way ANOVA followed by Bonferroni's multiple comparisons test. **d**, UMAP projection of $\gamma\delta$ T cells colored by the scaled expression of *Slc6a13* (GAT2). **e**, Average expression of chemokines in CD45⁺ cells isolated from steady state dura mater obtained from public database²¹. **f**, Representative histogram of the expression of CXCR6-GFP in meningeal T cell subsets. **g**, Absolute numbers of conventional $\alpha\beta$ T cells isolated from CXCR6–sufficient and –deficient mice. Unpaired two-tailed t test. Data represent one independent experiment. **h**, Adult *Ccr2^{CreERT2}:Ai6* mice were injected daily with tamoxifen (i.p., 10 mg/kg) and three days later meninges, spleen and blood were harvested for FACS analysis. Representative histograms of CCR2-ZsGreen expression in $\gamma\delta$ T cells and conventional $\alpha\beta$ T lymphocytes by flow cytometry. **h_i**, Graph bars of the percentage of $\gamma\delta$ T cell– and **h_{ii}**, $\alpha\beta$ T cell– expressing CCR2-ZsGreen in spleen, blood and meninges. **h_{iii}**, Histograms of the expression of CCR2-ZsGreen in meningeal $\gamma\delta$ and $\alpha\beta$ T lymphocytes. **h_{iv}**, Frequency of CCR2–expressing cells. One-way ANOVA followed by Bonferroni's multiple comparisons test. **i**, Representative dot plots of the percentage of meningeal TCR $\gamma\delta$ – and TCR β – expressing cells isolated from WT or *Ccr2^{-/-}* (*Ccr2^{RFP/RFP}*) mice. **i_i**, Percentage and **i_{ii}**, absolute number of meningeal $\gamma\delta$ T cells. **i_{iv}**, Percentage and **i_v**, absolute number of meningeal $\alpha\beta$ T cells. Unpaired two-tailed t test. **j**, Dot plots of the frequency of inflammatory monocytes (CD11b^{hi}Ly6C^{hi}) isolated from WT or CCR2-deficient mice. **j_i**, Percentage and **j_{ii}**, absolute number of meningeal inflammatory monocytes. Data are pooled from two independent experiments with similar results. Unpaired two-tailed t test. **k**, Social interaction of wild-type and *Tcrd^{-/-}* mice was assessed in the three-chamber test and the percentage of time investigating either a mouse (social) or an object (inanimate) was calculated. WT (n = 9); *Tcrd^{-/-}* (n = 11). Two-way ANOVA followed by Bonferroni's multiple comparisons test. **l**, For the spatial memory task, WT and $\gamma\delta$ T cell-deficient mice were assessed in the training and **l_i**, novel location tasks of the novel location recognition (NLR) test and the time spent with either a familiar or novel object was determined. WT (n = 8); *Tcrd^{-/-}* (n = 8). Two-way ANOVA followed by Bonferroni's multiple comparisons test. **m**, Foraging behavior of wild-type and *Tcrd^{-/-}* mice assessed in the exploratory and **n**, foraging phase of the foraging paradigm. Data is pooled from three independent cohorts. WT (n = 18); *Tcrd^{-/-}* (n = 18); Unpaired two-tailed t test. Data are shown as mean \pm s.e.m. and each dot symbol represents individual mouse.




Extended Data Fig. 3 | See next page for caption.

Extended Data Fig. 3 | $\gamma\delta$ 17 T cells are localized in the meningeal stroma and actively transcribe IL-17a *in vivo*. **a**, Flow cytometry analysis of meninges three days after treatment with 2.5 μg of isotype control or anti-TCR $\gamma\delta$ (i.c.m.). **a_i**, Percentage of CD45⁺ live cells. **a_{ii}**, Frequency of $\alpha\beta$ T lymphocytes gated on the CD45⁺ fraction. **a_{iii}**, Absolute number of CD45⁺ leukocytes, **a_{iv}**, $\alpha\beta$ T cells and **a_v**, $\gamma\delta$ T cells in the meninges. Isotype control (n=3); anti-TCR $\gamma\delta$ (n=3). **b**, Absolute number of $\gamma\delta$ T cells of mice treated as described in **a**. To bypass their TCR staining, $\gamma\delta$ T cells were gated as Thy1.2⁺TCR β^{neg} ROR γ t⁺ cells. Isotype control (n=4); anti-TCR $\gamma\delta$ (n=4). **c**, Levels of TCR $\gamma\delta$ expression in splenic $\gamma\delta$ T cells three days after treatment with 2.5 μg of isotype control or anti-TCR $\gamma\delta$ (i.c.m.). Isotype control (n=4); anti-TCR $\gamma\delta$ (n=4). **d**, Expression per cell of IL-17a in Thy1.2⁺TCR β^{neg} ROR γ t⁺IL-17a⁺ T cells (“visible” and “invisible” $\gamma\delta$ T cells). Isotype control (n=4); anti-TCR $\gamma\delta$ (n=4). **e**, WT mice were injected with 2.5 μg of anti-TCR $\gamma\delta$ or isotype control (i.c.m.) and seven days later were assessed in the elevated plus maze. Representative track plots of the cumulated movement. **e_i**, Percentage time spent in the open arms of the maze. Isotype control (n=10); anti-TCR $\gamma\delta$ (n=10). **f**, Representative histogram of the levels of TCR $\gamma\delta$ expression in meningeal $\gamma\delta$ 17 T cells seven days after injection with isotype control or anti-TCR $\gamma\delta$. **f_i**, Contour plots of the percentage of IL-17a[–] and IFN γ –producing meningeal T lymphocytes. **f_{ii}**, Absolute number of meningeal $\gamma\delta$ T cells. **f_{iii}**, Analysis of the TCR $\gamma\delta$ MFI (gated on $\gamma\delta$ T cells). **f_{iv}**, Graph bars for the percentage of IL-17a[–] producing meningeal $\gamma\delta$ T cells or **f_v**, $\alpha\beta$ T cells. Isotype control (n=3); anti-TCR $\gamma\delta$ (n=3). **g**, Homeostatic IL-17a-eGFP expression in meningeal T cell by immunohistochemistry using the IL-17a reporter mice (*Il17a^{eGFP/eGFP}*). Insets of the superior sagittal sinus (SSS) of meningeal dural whole-mounts showing CD3 (red), IL-17a (eGFP, green) and CD31 (blue) staining in adult mice. White arrows highlight $\gamma\delta$ T cells (defined by the CD3 and IL-17a double-staining). Scale bar, 100 μm . Representative image of at least three independent experiments with similar results (n=3 per experiment). **h**, Representative FACS plot of the IL-17a-eGFP expression of meningeal and splenic $\gamma\delta$ T cells under steady state. **h_i**, Graph bars of IL-17a[–] expressing cells in the meninges or **h_{ii}**, spleen (n=3 per group). **i**, Representative dot plots of IL-17a-eGFP⁺ meningeal T cells three days after treatment with 2.5 μg of anti-TCR $\gamma\delta$ treatment (i.c.m.). To bypass their TCR staining, “visible” and “invisible” $\gamma\delta$ T cells were gated as Thy1.2⁺ROR γ t⁺ cells. **i_i**, Frequency of IL-17a-eGFP⁺ meningeal $\gamma\delta$ 17 T cells (defined as Thy1.2⁺ROR γ t⁺TCR β^{neg} cells). **i_{ii}**, IL-17a expression per a cell basis on IL-17a-eGFP[–] expressing $\gamma\delta$ T cells. Isotype control (n=5); anti-TCR $\gamma\delta$ (n=5). **j**, Scheme of the experimental approach used to label intravascular and tissue-localized cells in steady state meninges. WT mice were given 0.25 μg of anti-CD45 (i.v.) and 3 min later blood was collected. Animals were perfused, and meninges were harvested for flow cytometry analysis. **j_i**, Representative dot plots and **j_{ii}**, Graph bars of either intravascular (i.v. CD45⁺) or tissue-localized (i.v. CD45^{neg}) $\gamma\delta$ T cells (n=4 per group). **k**, Representative meningeal coronal section of IL-17a-eGFP reporter mice stained for DAPI (blue), CD31 (white), and CD3 (red). Arrows indicate a T cell expressing IL-17a-eGFP in meningeal stroma. Scale bar, 100 μm . Representative image of one single experiment (n=5). **l**, MSD assay of CSF obtained from WT and *Tcrd*^{–/–} mice. Technical replicate of meninges pooled from WT or *Tcrd*^{–/–} mice (n=10 per group). ND, not detected. **m**, Steady state concentration of plasmatic IL-17a obtained from WT and *Tcrd*^{–/–} mice by MSD assay (n=6 per group). Data are shown as mean \pm s.e.m. and each dot symbol represents individual mouse. **a–f**, **h**, **i**, and **m**, Unpaired two-tailed t test.




Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Pathways and stimuli involved in the activation of meningeal $\gamma\delta 17$ T cells. **a**, Stress was induced in IL-17a-eGFP mice by the exposure to electrical foot shock (ES) for seven consecutive days. **a_i**, Representative dot plots of the IL-17a-eGFP expression by meningeal T cells by flow cytometry. **a_{ii}**, Frequency of IL-17a-eGFP⁺ $\gamma\delta 17$ T cells or **a_{iii}**, conventional $\alpha\beta$ T cells. Data are from one single experiment. Naive (n=5); ES (n=5). **b**, Unpredictable chronic mild stress (UCMS) was induced for over eight weeks in WT mice. **b_i**, Representative expression of IL-17a and IFN γ assessed by the intracellular staining following *ex vivo* stimulation. **b_{ii}**, Percentage of IL-17a- or **b_{iii}**, IFN γ - producing $\gamma\delta$ T cells. Naive (n=4); UCMS (n=5). Data are from one single experiment. **c**, Percentage of conventional $\alpha\beta$ and $\gamma\delta$ T cells isolated from meninges of specific pathogen free (SPF) and germ-free mice. **c_i**, Representative contour plots of the percentage of IL-17a-positive meningeal $\gamma\delta$ cells. **c_{ii}**, Graph bars of the frequency and **c_{iii}**, absolute number of meningeal $\gamma\delta$ T lymphocytes in SPF versus germ-free animals. **c_{iv}**, Analysis of the frequency and **c_v**, absolute number of meningeal $\gamma\delta$ T cell-producing IL-17a. SPF (n=5); Germ-free (n=5). **d**, Contour plots of the percentage of IL-17a-positive meningeal $\gamma\delta$ cells obtained from meninges of untreated (No Abx) or broad-spectrum antibiotics-treated (Abx) animals and assessed by *ex vivo* stimulation. **d_i**, Graph bars of the frequency and **d_{ii}**, absolute number of IL-17a-producing meningeal $\gamma\delta$ T lymphocytes. No Abx (n=3); Abx (n=4). **e**, Representative contour plots of IL-17a and IFN γ expression by meningeal $\gamma\delta$ T cells 24 h after aryl hydrocarbon receptor (AHR) activation by the endogenous ligand 6-Formylindolo[3,2-b]carbazole (FICZ, 10 ng, *i.c.m.*). **e_i**, Analysis of the frequency of IL-17a- and **e_{ii}**, IFN γ - producing cells assessed by *ex vivo* stimulation. N=3 per group. **f**, Representative dot plots of the percentage of TCR $\gamma\delta$ - or $\alpha\beta$ -expressing cells obtained from WT or *Il1r1*^{-/-} mice. **f_i**, Analysis of the percentage and **f_{ii}**, absolute number of meningeal $\gamma\delta$ T cells. **f_{iii}**, Graph bars of the frequency and **f_{iv}**, absolute number of meningeal $\alpha\beta$ T lymphocytes. WT (n=5); *Il1r1*^{-/-} (n=5). **g**, Contour plots of the IL-17a expression by meningeal $\gamma\delta$ T cells following the *ex vivo* stimulation by PMA/Ionomycin. **g_i**, Analysis of the percentage and **g_{ii}**, absolute number of IL-17a-producing $\gamma\delta$ T cells. WT (n=5); *Il1r1*^{-/-} (n=5). **h**, Representative dot plots of the percentage of TCR $\gamma\delta$ - or $\alpha\beta$ -expressing cells obtained from WT or *Il23a*^{-/-} mice. **h_i**, Analysis of the frequency and **h_{ii}**, absolute number of meningeal $\gamma\delta$ T cells. **h_{iii}**, Graph bars of the percentage and **h_{iv}**, absolute number of meningeal $\alpha\beta$ T lymphocytes. WT (n=3); *Il23a*^{-/-} (n=3). **i**, Contour plots of the IL-17a and IFN γ expression by meningeal $\gamma\delta$ T cells following *ex vivo* stimulation. **i_i**, Analysis of the percentage and **i_{ii}**, absolute number of IL-17a-producing $\gamma\delta$ T cells. WT (n=3); *Il23a*^{-/-} (n=3). **j**, Representative contour plots of the percentage of IL-17a-eGFP⁺ meningeal T cells seven days after active EAE induction (EAE 7dpi). **j_i**, Graph bars of the frequency of meningeal $\gamma\delta$ T lymphocytes (total TCR $\gamma\delta$ ⁺ cells), **j_{ii}**, conventional $\alpha\beta$ T cells (TCR β ⁺ cells) and **j_{iii}**, V $\gamma 2$ ⁺ $\gamma\delta$ T cells (gated on total $\gamma\delta$ T cells). **j_{iv}**, Percentage of IL-17a-eGFP⁺ cells gated on innate-like $\gamma\delta$ T cells (V $\gamma 2$ ^{neg}) and **j_v**, expression per cell of IL-17a. **j_{vi}**, Frequency of IL-17a-eGFP⁺ $\alpha\beta$ T cells. Naive (n=4); EAE (n=5). **k**, Representative contour plots of the percentage of IL-17a-eGFP⁺ meningeal T cells 14 days post EAE induction (EAE 14dpi). **k_i**, Graph bars of the frequency of meningeal $\gamma\delta$ T lymphocytes (TCR $\gamma\delta$ ⁺ cells), **k_{ii}**, $\alpha\beta$ T cells and **k_{iii}**, V $\gamma 2$ ⁺ $\gamma\delta$ T cells (gated on $\gamma\delta$ T cells). **k_{iv}**, Percentage of IL-17a-eGFP⁺ cells gated on innate-like $\gamma\delta$ T cells (V $\gamma 2$ ^{neg}) and **k_v**, expression per cell of IL-17a-eGFP. **k_{vi}**, Frequency of IL-17a-eGFP⁺ cells in $\alpha\beta$ T cells. Naive (n=4); EAE (n=4). Data are shown as mean \pm s.e.m. and each dot symbol represents individual mouse. **a-k**, Unpaired two-tailed t test.




Extended Data Fig. 5 | Lack IL-17a signaling does not affect social or learning behaviors. **a**, Representative track plots of the cumulative total distance of *Il17a^{+/-}* and *Il17a^{-/-}* mice in the elevated plus maze test. **a_{ii}**, Percentage of total time spent in the open arms. *Il17a^{+/-}* (n=11) and *Il17a^{-/-}* (n=10). Unpaired two-tailed t test. **b**, Representative images of IL-17Ra (green), NeuN (red) and DAPI (blue) staining in the PFC, **c**, hippocampus and **d**, cerebellum of WT mice. **b-d**, Representative image of at least three independent experiments with similar results (n=3 per experiment). Scale bar, 100 μ m. **e**, Expression of *Il17ra* (Cyan) at anterior-posterior (AP) +1.32 mm, **f**, AP: -2.75 and **g**, in the cerebellum by *in situ* hybridization. **e, f**, Scale bar, 500 μ m. **g**, Scale bar, 100 μ m. *Il17ra* (Cyan) was co-labelled with GABAergic (*Gad2*, green), glutamatergic markers (*Slc17a7*, magenta), and DAPI (blue). **e-g**, Representative image of 5 independent experiments with similar results (n=3 per experiment). **h**, AAV *Syn1^{Cre}* was bilaterally injected into the mPFC of WT or *Il17ra^{fl/fl}* mice. Four weeks later, mPFC slices were prepared for immunohistochemistry analysis. **h_i**, Representative images of IL-17Ra expression in the mPFC of WT or *Il17ra^{fl/fl}* mice. **h_{ii}**, Analysis of the efficiency transfection. **h_{iii}**, Coverage of IL-17Ra staining and **h_{iv}**, Quantification of IL-17Ra-positive cells as a fraction of total NeuN⁺ cells. Scale bar, 30 μ m. WT (n=5) and *Il17ra^{fl/fl}* (n=5), with 20 slices per mouse. Unpaired two-tailed t test. **i**, Sociability assay was performed in the three-chamber test and the percentage of time investigating either a mouse (social) or an object (inanimate) was calculated. WT (n=9) and *Il17ra^{fl/fl}* (n=11). Two-way ANOVA followed by Bonferroni's multiple comparisons test. **j**, In the fear conditioning paradigm, the percentage of time freezing was evaluated in the context and **j_i**, cued trial. WT: AAV *Syn1^{Cre}* (n=10) and *Il17ra^{fl/fl}*: AAV *Syn1^{Cre}* (n=9). **k**, AAV *Syn1^{Cre}* was bilaterally injected into the S1DZ region of WT or *Il17ra^{fl/fl}* mice. Mice were tested in the elevated plus maze four weeks later. Percentage of total time spent in the open arms of the maze is presented. WT (n=8) and *Il17ra^{fl/fl}* (n=10). Unpaired two-tailed t test. Data represents one single experiment. Data is presented as mean \pm s.e.m. and each dot symbol represents individual mouse.




Extended Data Fig. 6 | See next page for caption.

Extended Data Fig. 6 | Neuronal loss of IL-17a signaling changes the transcriptional landscape of mPFC neurons. **a_i**, Representative track plots of the cumulative total distance of *Syn1^{Cre}*, *Il17ra^{fl/fl}* and *Syn1^{Cre}:Il17ra^{fl/fl}* tested in the elevated plus maze test just before nuclei isolation for the scRNA-Seq experiment. **a_{ii}**, Percentage of total time spent in the open arms. *Il17ra^{fl/fl}* (n = 5); *Syn1^{Cre}* (n = 5); and *Syn1^{Cre}:Il17ra^{fl/fl}* (n = 4). Data represents one single experiment. *Il17ra^{fl/fl}* vs. *Syn1^{Cre}:Il17ra^{fl/fl}*, $P = 0.049$; *Syn1^{Cre}* vs. *Syn1^{Cre}:Il17ra^{fl/fl}*, $P = 0.011$; One-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons test. **b**, Heatmap showing cluster signatures across all mPFC nuclei. Each line represents the scaled expression of the corresponding gene within each nucleus, with more highly expressed genes shown in black. The top five most highly expressed genes from each cluster (compared against all other clusters) are shown. **c**, Dot plot showing the expression of canonical neuronal subclass markers across each of our Seurat identified clusters. Color represents the scaled average expression and size indicates the percentage of cells within each cluster expressing the gene. **d_i**, Dot plot showing the expression of *Slc17a7*, *Gad2* and *Il17ra* among 2,590 nuclei isolated from the mouse hippocampus (dentate gyrus). Color represents the scaled average expression and size indicates the percentage of cells within each cluster expressing the gene. **d_{ii}**, violins show the normalized expression of *Il17ra* within each cell across clusters. **e**, Bar graph showing the proportion of cells from each sample belonging to each cluster across all mPFC nuclei. **f**, Violins show the normalized expression of *Il17ra* within each cell across clusters. **g**, Dot plot showing information about each cluster. In the top row, dot size indicates the total number of cells belonging to the cluster and color indicates the number of differentially expressed genes (DEG) overlapping between *Syn1^{Cre}:Il17ra^{fl/fl}* vs. *Syn1^{Cre}* and *Syn1^{Cre}:Il17ra^{fl/fl}* vs. *Il17ra^{fl/fl}* (adjusted p value < 0.05, absolute log fold change > 0.1). In the second row, the size of the dot shows the percentage of cells within the cluster expressing *Il17ra* while the color represents the scaled average expression of *Il17ra* across cells in the cluster. **h**, Heatmaps showing overlapping differentially expressed genes between *Syn1^{Cre}:Il17ra^{fl/fl}* vs. *Syn1^{Cre}* and *Syn1^{Cre}:Il17ra^{fl/fl}* vs. *Il17ra^{fl/fl}* that are significantly changed in all three layer subsets (far left), the top 50 (based on absolute average log fold change) differentially expressed genes that changed uniquely in Layer II/III (left), and the significantly differentially expressed genes that were uniquely changed in Layer V (right) and Layer VI (far right) with the loss of functional *Il17ra*. Above each heatmap is a pie chart showing the percentage of significantly differentially expressed genes combined across all layers, that belong to each category described (shared, unique to Layer II/III, unique to Layer V, or unique to Layer VI). **i**, Plots showing the most significantly enriched KEGG pathways based on the set of significantly up- (top) or down- (bottom) regulated genes shared between *Syn1^{Cre}:Il17ra^{fl/fl}* vs. *Syn1^{Cre}* and *Syn1^{Cre}:Il17ra^{fl/fl}* vs. *Il17ra^{fl/fl}* with colored squares indicating the contribution of each gene to the corresponding enriched pathway.



Extended Data Fig. 7 | See next page for caption.

Extended Data Fig. 7 | IL-17a effects on electrophysiological parameters of mPFC neurons. a-f, Spontaneous excitatory postsynaptic action potentials (sEPSCs) in the mouse mPFC before and after IL-17a application via bath-application for 20 to 25 min ($n = 8$ neurons). The data points represent sEPSCs frequency or amplitude on a given neuron pre- and post- IL-17a treatment (blue and orange dots respectively – plotted on the right y-axis). Light grey bars represent the frequency or peak amplitude (pA) as % of control in the given neuron (mean and s.e.m., plotted on the left y-axis). **a_i**, Recordings of spontaneous action potentials before (pre) and after (post) IL-17a application (1 ng/mL). **a_{ii}**, Frequency of spontaneous action potentials pre and post treatment of 1 ng/mL of IL-17a. **b_i**, Representative amplitude of the spontaneous excitatory postsynaptic action potentials in the mouse mPFC before and after application of IL-17a (1 ng/ml) as described before. **b_{ii}**, Analysis of the peak amplitude. **c_i**, Recordings of spontaneous action potentials before and after IL-17a application (10 ng/mL). **c_{ii}**, Frequency of spontaneous action potentials pre and post treatment of 10 ng/mL of IL-17a. **d_i**, Representative amplitude of the spontaneous excitatory postsynaptic action potentials before and after application of IL-17a (10 ng/ml). **d_{ii}**, Analysis of the peak amplitude. **e_i**, Recordings of spontaneous action potentials before and after IL-17a application (100 ng/mL). **e_{ii}**, Frequency of spontaneous action potentials pre and post treatment of 100 ng/mL of IL-17a. **f_i**, Representative amplitude of the spontaneous excitatory postsynaptic action potentials before and after application of IL-17a (100 ng/ml). **f_{ii}**, Analysis of the peak amplitude. **g-l,** Spontaneous inhibitory postsynaptic action potentials (sIPSCs) in the mouse mPFC before and after IL-17a application via bath-application for 20 to 25 min ($n = 8$ neurons). **g_i**, Recordings of spontaneous action potentials before and after IL-17a application (1 ng/mL). **g_{ii}**, Frequency of spontaneous action potentials pre and post treatment of 1 ng/mL of IL-17a. **h_i**, Representative amplitude of the spontaneous inhibitory postsynaptic action potentials before and after application of IL-17a (1 ng/ml). **h_{ii}**, Analysis of the peak amplitude. **i_i**, Recordings of spontaneous action potentials before and after IL-17a application (10 ng/mL). **i_{ii}**, Frequency of spontaneous action potentials pre and post treatment of 10 ng/mL of IL-17a. **j_i**, Representative amplitude of the spontaneous inhibitory postsynaptic action potentials before and after application of IL-17a (10 ng/ml). **j_{ii}**, Analysis of the peak amplitude. **k_i**, Recordings of spontaneous action potentials before and after IL-17a application (100 ng/mL). **k_{ii}**, Frequency of spontaneous action potentials pre and post treatment of 100 ng/mL of IL-17a. **l_i**, Representative amplitude of the spontaneous inhibitory postsynaptic action potentials before and after application of IL-17a (100 ng/ml). **l_{ii}**, Analysis of the peak amplitude. **a-l**, Wilcoxon matched-pairs signed rank test.



Extended Data Fig. 8 | IL-17a effects on the evoked action potentials before and after IL-17a treatment. **a_{i-iii}**, Recordings of evoked action potentials in a neuron in the mouse mPFC before (pre) and after (post) IL-17a application ($n = 8$ neurons). The current injection protocol ($-40, 0, 40, 80, 120, 160, 200$ pA; 500 ms) is shown in gray underneath the traces. **b_{i-iii}**, Graphs show the frequency of action potentials (y-axis) in response to different levels of current injection (x-axis) before and after IL-17a bath-application for 20 to 25 min. **b_{iv}**, Graph summarizes the change in frequency pre and post IL-17a treatment. Two-way ANOVA followed by Sidak's multiple comparisons test. Data points and error bars represent the mean and s.e.m., respectively, of $n = 8$ sets (Pre vs. Post IL-17a treatment). **c_i**, Scheme of the experimental details to target IL-17a–responding cells. *Fos^{CreERT2}; Ai14* mice were treated with 25 ng of IL-17a or saline (i.c.m.) and then given an injection of 4-hydroxytamoxifen (4-OHT, i.p.) one hour later. After seven days, animals were perfused and the mPFC was collected for immunohistochemistry staining and analysis. **c_{ii}**, Representative photomicrographs from the mPFC of mice injected with IL-17a or saline and stained for a neuronal marker, NeuN (blue), DAPI (red) and showing c-Fos expression (green). **c_{iii}**, Quantification of c-Fos⁺ cells in the mPFC of stimulated mice. Scale bar, 200 μ m. aCSF ($n = 5$); IL-17a ($n = 5$). Unpaired two-tailed t test. Representative image of two independent experiments with similar results ($n = 5$ per experiment). Data is presented as mean \pm s.e.m. and each dot symbol represents individual mouse.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-----|-----------|
| n/a | Confirmed |
|-----|-----------|
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
 - A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
 - The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
 - A description of all covariates tested
 - A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
 - A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
 - For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
 - For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
 - For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
 - Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

- Gallios Flow Cytometer (Beckman Coulter)
- BD Influx Cell Sorter
- CyTOF Helios Mass Cytometer
- 10x Genomics Chromium instrument
- Illumina NextSeq 500 platform
- Leica TCS SP8 confocal system (Leica Microsystems)
- Leica VT1000s
- MultiClamp 700B (Molecular Devices)
- Digidata 1440 data acquisition system (Molecular Devices)
- Phase contrast microscope (Olympus BX51WI)
- TopScan Suite, CleverSys, Inc.
- Noldus Ethovision XT
- Etholog v2.2

Data analysis

- GraphPad Prism v8 (GraphPad Software Inc)
- FlowJo version (v) 10 (TreeStar)
- R 3.6.3
- FIJI image processing software (NIH) - v2.00-rc-59/1.51n
- MATLAB R2017b (Mathworks)
- Cytobank 7.2.1
- FastQC v0.11.5
- Illumina Bcl2fastq v2.20 (Illumina)
- Cell Ranger 3.0 (10x Genomics)

- Droplet Utils 3.11 (Bioconductor)
- Seurat pipeline (Satijalab)
- pClamp (version 10.4 and 10.7, Molecular Devices)
- RphenoGraph Clustering algorithm (cytofkit, version 1.4.8)
- clusterProfiler package v3.0.4

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Fastq files and quantified gene counts for scRNA-Seq ara available at the Gene Expression Omnibus (GEO) under accession number GSE147262.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

- Sample size: The n sample was determined based on previous publications and/or internal pilot data, to be adequate for statistical analysis and ensured reproducibility. No statistical methods were used to determine the sample size.
- Data exclusions: No data exclusions.
- Replication: Different number of mice were used for each experiment. Each experiment was repeated at least twice. All attempts at repeating were successful.
- Randomization: Randomization was performed for all the in vivo experiments requiring group divisions. We ensured that age and gender were always matched between groups.
- Blinding: Experimental groups were blinded during scoring and quantifications.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | n/a | Involved in the study |
|-------------------------------------|---|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Antibodies |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Animals and other organisms |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Human research participants |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern |

Methods

- | n/a | Involved in the study |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Antibodies

Antibodies used

A detailed list with the antibodies used in this study is presented in Supplementary Information Table 3. Anti-mouse antibodies for extracellular markers were used at 1:300 dilution. For intracellular staining, antibodies were diluted at 1:250. CD3e-APC-Cy7 (BD, Clone: 145-2C11, #Cat: 561042); CD3e-eFluor 450 (eBioscience, Clone: 145-2C11, #Cat: 48-0031-82); CD4-APC (eBioscience, Clone: GK 1.5, #Cat: 17-0041-82); CD4-FITC (BioLegend, Clone: GK 1.5, #Cat: 100406); CD4-PE (BD, Clone: RM4-5, #Cat:

553049); CD8a-FITC (BD, Clone: 53-6.7, #Cat: 553031); CD8a-PE-Cy7 (BioLegend, Clone: 53-6.7, #Cat: 100722); CD11b-PE-Cy7 (eBioscience, Clone: M1/70, #Cat: 25-0112-82); CD44-APC (BD, Clone: IM7, #Cat: 559250); CD44-APC-eFluor 780 (eBioscience, Clone: IM7, #Cat: 47-0441-82); CD44-BB515 (BD, Clone: IM7, #Cat: 565941); CD45-APC (BD, Clone: 30-F11, #Cat: 559864); CD45-APC-Cy7 (BD, Clone: 30-F11, #Cat: 557659); CD45-eFluor 450 (eBioscience, Clone: 30-F11, #Cat: 48-0451-82); CD45-PerCP Cy5.5 (BD, Clone: 30-F11, #Cat: 550994); CD45.1-eFluor 450 (eBioscience, Clone: A20, #Cat: 48-0453-82); CD45.1-PE (eBioscience, Clone: A20, #Cat: 12-0453-82); CD45.2-APC (eBioscience, Clone: 104, #Cat: 17-0454-82); CD62L-PE (eBioscience, Clone: MEL-14, #Cat: 12-0621-82); CD69-PE (eBioscience, Clone: H1.2F3, #Cat: 12-0691-82); CD69-PE-Cy7 (BD, Clone: H1.2F3, #Cat: 552879); CD121a (IL-1R)-PE (BioLegend, Clone: JAMA-147, #Cat: 113505); IFN gamma-APC (eBioscience, Clone: XMG1.2, #Cat: 17-7311-82); IFN gamma-FITC (BD, Clone: XMG1.2, #Cat: 554411); IL-17a-BV421 (BD, Clone: TC11-18H10, #Cat: 563354); IL-17a-PE (eBioscience, Clone: eBio17B7, #Cat: 12-7177-81); IL-17a-PerCP Cy5.5 (eBioscience, Clone: eBio17B7, #Cat: 45-7177-82); IL-22-PE (BioLegend, Clone: Poly5164, #Cat: 516404); Ki67-PE (BioLegend, Clone: 16A8, #Cat: 652404); Ly6C-PerCP Cy5.5 (BioLegend, Clone: HK1.4, #Cat: 128028); NK1.1-APC-eFluor 780 (eBioscience, Clone: PK136, #Cat: 47-5941-82); NK1.1-FITC (eBioscience, Clone: PK136, #Cat: 11-5941-82); NK1.1-PE-Cy7 (BD, Clone: PK136, #Cat: 552878); RORgammat-APC (eBioscience, Clone: B2D, #Cat: 17-6981-82); TCR beta-FITC (BioLegend, Clone: H57-597, #Cat: 109206); TCR beta-BV510 (BD, Clone: H57-597, #Cat: 563221); TCR gamma/delta-Alexa Fluor 647 (BioLegend, Clone: GL3, #Cat: 118134); TCR gamma/delta-FITC (BD, Clone: GL3, #Cat: 561996); TCR gamma/delta-PE (BioLegend, Clone: GL3, #Cat: 118108); TCR V gamma 1.1-PE (BioLegend, Clone: 2.11, #Cat: 141108); TCR V gamma 2-PE (BioLegend, Clone: UC3-10A6, #Cat: 137706); TCR V gamma 3-PE (BioLegend, Clone: 536, #Cat: 137504); Thy1.2/CD90.2-APC (BioLegend, Clone: 53-2.1, #Cat: 140312); Thy1.2/CD90.2-PE-Cy7 (BioLegend, Clone: 53-2.1, #Cat: 140310); Zombie Viability Dye-NIR (BioLegend, #Cat: 423106); Zombie Viability Dye-Aqua (BioLegend, #Cat: 423102); CD3- Alexa Fluor 488 (BD, Clone: SP34-2, #Cat: 557705); CD45-PerCP Cy5.5 (BD, Clone: HI30, #Cat: 564105); CD69-APC-H7 (BD, Clone: FN50, #Cat: 560737); TCR gamma/delta-BV421 (BD, Clone: B1, Cat: 562560).

Validation

All the antibodies used are commercially available and validated by the manufacturers. Isotype controls and/or fluorescence minus one (FMO) staining were performed as controls.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

All mice were either bred in-house or purchased from Jackson Laboratory. Most of our studies were performed in male mice and our key findings were also tested in females. Animals were kept in a specific-pathogen-free facility (temperatures of 65-75 F (18-23 C) with 40-60% humidity and 12-hour light/12-hour dark cycle.

Il23a-/- (Genentech)

C57BL/6J (JAX no: 000664)

Tcrd-CreERT2: B6.129S-Tcrdtm1.1(cre/ERT2)Zhu/J (JAX No: 031679)

Ai6: B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/J (JAX: 007906)

Ai14: B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J (JAX: 007914)

CXCR6-GFP: B6.129P2-Cxcr6tm1Litt/J (JAX: 005693)

Il1r1-/-: B6.129S7-Il1r1tm1Imx/J (JAX: 003245)

Syn1Cre: B6.Cg-Tg(Syn1-cre)671Jxm/J (JAX: 003966)

Ccr2-RFP: B6.129(Cg)-Ccr2tm2.1Ifc/J (JAX: 017586)

CD45.1: B6.SJL-Ptprca Pepcb/BoyJ (JAX No: 002014)

Tcrd-/-: B6.129P2-Tcrdtm1Mom/J (JAX No: 002120)

Il17a-eGFP: C57BL/6-Il17atm1Bcgen/J (JAX No: 018472)

Il17a-/-: Il17atm1.1(cre)Stck/J (JAX No: 016879)

Fos-CreERT2: Fostm2.1(cre/ERT2)Luo/J (JAX No: 030323)

Il17a-fl/fl: Il17ratm2.1Koll/J (JAX No: 031000)

Wild animals

This study did NOT involve wild animals.

Field-collected samples

This study did NOT involve field-collected samples.

Ethics oversight

All experiments were approved by the Institutional Animal Care and Use Committee of the University of Virginia.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

Patients were adults aging between 50-70 years old and with no previous record of neurological diseases.

Recruitment

Autopsy specimens of human dura were obtained from the Department of Pathology at the University of Virginia.

Ethics oversight

All autopsy specimens were from consenting patients that gave no restriction to the use of their body for research and teaching (through an UVA's Institutional Review Board for health Sciences Research)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Meninges were dissected as previously described and digested for 15 min at 37 °C with 1.4 U/mL of Collagenase VIII (Sigma Aldrich) and 35 U/mL of DNase I (Sigma Aldrich) in IMDM (Sigma Aldrich) media. Following the digestion step, the tissue was gently pressed through 70 µm nylon mesh cell strainers. Cells were then centrifuged at 450g at 4°C for 4 min. The cell pellets were resuspended in ice-cold FACS buffer (2 mM EDTA, 25 mM HEPES, 1% BSA in 1X PBS) and stained for extracellular markers at 1:300 dilution.

For intracellular staining single-cell isolates from meninges were stimulated 4 h in IMDM (supplemented with 1X non-essential amino acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 50 µM β-mercaptoethanol, 1 mM sodium pyruvate, and 10% FBS, all for Gibco) with PMA/ionomycin (Cell Stimulation Cocktail – eBioscience) and 1X brefeldin A (eBioscience) at 37°C before extracellular staining as stated above. Cells were then permeabilized with Foxp3/Transcription Factor Staining Buffer

Instrument

Acquisition was performed using Kaluza Acquisition software for Gallios.

Software

Analysis was performed using FlowJo V10 (TreeStar).

Cell population abundance

N/A

Gating strategy

Single cells were discriminated in a FSC-H vs. FSC-A plot. From the selected singlets, dead cells were excluded by gating out on live/dead dye negative population (Live/dead dye vs. CD45). Further gating strategy is indicated above each FACS plot. Positive or negative populations were defined by using Isotype controls and/or FMO.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.